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The prevalence of metabolic disease continues to rise in the United States, leading to 
conditions such as metabolic syndrome, diabetes, and NAFLD. Heat shock proteins (HSPs) are 
molecular chaperones which aid in protein folding during cellular stress. These proteins are also 
important in metabolic function, through inhibiting inflammation and increasing oxidative 
capacity in skeletal muscle. Reduced HSPs may also lead to metabolic disease, demonstrated 
by reduced HSP72 expression in skeletal muscle of diabetic patients and in the liver with the 
progression of NAFLD.  
 Our studies further demonstrate that disruption in the HSP response could be an 
underlying commonality in various metabolic conditions and tissues. First, we found that a 
reduction in HSPs in skeletal muscle of a post-menopausal rat model is associated with reduced 
mitochondrial protein expression, increased lipid storage, and reduced exercise capacity. We 
also investigated the role of HSP72 in the liver. A loss of HSP72 in hepatocytes led to a 
reduction in fatty acid oxidation, mitochondrial dysfunction, and increased lipid storage. A 
reduction in HSPs in both the skeletal muscle and the liver may increase susceptibility to the 
development of metabolic disease.  
Our work also demonstrates that activation of HSPs has potential to protect from 
metabolic dysfunction. We found that a heat treatment intervention increases HSP72 in the liver, 
reduces hepatic triglyceride storage, and improves whole-body glucose homeostasis in rodents 
fed a high-fat diet. We also found that acute and chronic exercise increase HSP72 protein 
expression in the liver. The induction of HSPs with exercise was associated with changes in 
autophagy and mitophagy protein expression, which may protect hepatocytes from 
accumulation of damaged organelles. This work strongly suggests that HSP72 maintains whole-
body metabolic homeostasis through protecting against lipid accumulation in both skeletal 
muscle and liver. Therapies which activate HSP72 may be the key to protecting against 
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1.1 Obesity and Metabolic Syndrome  
1.1.1 Epidemiology  
Obesity is a significant health concern in the United States that is predicted to affect half 
of Americans by 2030 [1]. This places an immense burden on our health care system, as the 
yearly cost in the United States for obesity is $147 billion dollars [1]. Metabolic syndrome 
develops over time and is a collection of factors including abdominal obesity, dyslipidemia, 
hypertension and glucose intolerance stemming from metabolic dysfunction [2]. Obesity and 
metabolic syndrome put people at risk for many other health complications such as type 2 
diabetes, cardiovascular disease, and stroke. This health crisis is not slowing, as one in six 
children in the United States are obese [3]. Due to the high prevalence, the medical community 
is in need of novel and more effective strategies for prevention and treatment of metabolic 
syndrome.  
Insulin resistance is a major component of metabolic dysfunction. Due to high blood 
glucose, inflammation and lipid toxicity, metabolic tissues such as skeletal muscle and the liver 
become insulin insensitive over time. This results in dysregulation of gluconeogenesis by the 
liver, and decreased ability of skeletal muscle to perform glucose uptake [4, 5]. At the beginning 
of metabolic dysfunction development, pancreatic β-cells overproduce insulin in order to 
compensate for insulin resistance in metabolic tissues. However, the hormone no longer 
effectively clears glucose from the blood. Eventually with the progression into type 2 diabetes, 
β-cells are not able to produce sufficient insulin [6]. 
1.1.2 Risk Factors and Current Treatment 
There are many factors that affect a person’s susceptibility to metabolic syndrome. 
Obesity, excess nutrition, sedentary behavior, insulin resistance and family history of the 
disease are all risk factors for development of metabolic syndrome. Certain racial groups, such 
as Hispanics, are more susceptible to developing metabolic syndrome [7]. The first treatment 
3 
 
option for metabolic syndrome involves lifestyle changes such as physical activity and improved 
nutrition [7]. If lifestyle changes are not sufficient, surgery and medication are also options. 
Bariatric surgery has become a common strategy to decrease obesity [8]. Medications which 
control blood pressure, cholesterol levels, and blood glucose are also typically used.  Insulin 
sensitizers, such as metformin and thiazolidinediones (TZDs), are a main form of treatment in 
patients with advancing diabetes [9, 10].  
 
1.2 Metabolic Dysfunction in Postmenopausal Women 
The development of insulin resistance in skeletal muscle and systemically is a critical 
step towards diabetes, and often occurs in post-menopausal women [11]. Estrogen’s most 
studied role is in reproductive tissues, but estrogen is also important in many non-reproductive 
tissues [12, 13]. Estrogen therapy can ameliorate the increased risk of diabetes in 
postmenopausal women through improving metabolic homeostasis systemically and in skeletal 
muscle [14]. Clinical studies have been essential in identifying the role of estrogen in 
metabolism, but rodent models have allowed us to identify tissue-specific effects of estrogen 
action including the importance of estrogen action in skeletal muscle. Rodent models, such as 
ovariectomy and estrogen receptor knockout, have also deepened our understanding of the 
estrogen-mediated mechanisms. 
1.2.1 Susceptibility to Insulin Resistance in Male and Female Rodents 
Males and females exhibit variations in metabolic regulation and response to metabolic 
stressors. Although these variations have been observed in rodent and human research, studies 
investigating the effect of a high-fat diet (HFD) on weight gain in male versus female rodents 
has yielded inconsistent results. Some studies have found that female rodents gain significantly 
less body weight [15] and adipose tissue weight [15, 16] than male rodents on a HFD. Other 
studies have found that male and female rodents gain similar weight [16, 17] or that female 
rodents gain more body weight and adipose tissue than male rodents on a HFD [18-20]. 
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Variables that could significantly change the outcome in these studies are the species of rodent 
and also the duration and composition of HFD. Also, it is understandable that estrogen can be 
protective from metabolic dysfunction to only a certain extent before diet can overcome that 
protection. 
Although many studies are not in agreement with changes in weight gain with a HFD, 
one difference that has been consistently observed in past studies is decreased susceptibility to 
insulin resistance in female rodents following a HFD [17, 18, 21-25]. For example, Yakar et al. 
found that a 10-week HFD equally increased body weight and fat percentage in both male and 
female rodents, however male rodents demonstrated increased insulin resistance as measured 
by glucose and insulin tolerance tests, while females did not [22]. Other studies have found 
similar results regarding protection from insulin resistance in female rodents even without 
reduced weight gain compared to male rodents [17, 18]. In addition to reduced susceptibility to 
insulin resistance, female rodents show greater whole-body oxygen consumption compared to 
males [16, 26]. Both enhanced insulin sensitivity and oxygen consumption contribute to 
improved whole-body metabolism in female rodents. 
Insulin sensitivity and systemic metabolic homeostasis may be better maintained in 
female rodents on a HFD due to enhanced skeletal muscle metabolism. Many studies have 
demonstrated that a HFD in male rodents impairs skeletal muscle glucose metabolism [27-29], 
but not as many studies have compared males and females. In two different studies, 
researchers found metabolic differences in skeletal muscle that may protect female rodents 
from HFD-induced insulin resistance. Gomez et al. found that female rodents had higher 
triglyceride storage capacity in skeletal muscle [17] and adipose tissue and increased 
expression of fatty acid utilization genes in skeletal muscle [18]. Additionally, they found that 
stress and antioxidant enzyme activity in muscle was similar between genders, although female 
rodents demonstrated slightly higher skeletal muscle oxygen consumption and significantly 
higher cytochrome C oxidase (COX, the last enzyme in the respiratory electron transport chain) 
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activity than male rodents in response to a HFD. Skeletal muscle from female rodents also had 
increased Glut4 protein content, the main glucose transporter in skeletal muscle, and UCP3 
protein content, an uncoupling protein, in response to a HFD [17]. Uncoupling proteins (UCP) 
transfer hydrogen ions to the intermembrane space and can protect mitochondria from oxidative 
stress [30] with increased flux into the electron transport chain (ETC). Another study by Catala-
Niell et al. found that female rodents have reduced hydrogen peroxide production and increased 
antioxidant activity in skeletal muscle [16]. Although these studies found varying results, overall 
improved skeletal muscle metabolic function and flexibility in female rodents could be a defining 
factor in the protection from HFD-induced insulin resistance.  
1.2.2 Skeletal Muscle Metabolic Dysfunction following Ovariectomy 
Ovariectomy (OVX) in rodents is a model of human ovarian hormone loss that is seen in 
postmenopausal women.  Like in postmenopausal women, ovariectomy in rodents leads to 
increased metabolic dysfunction which results in increased weight gain and body fat [15, 22, 31-
42]. In addition to body weight changes, insulin sensitivity is impaired with a loss of estrogen 
[22, 39, 43, 44]. Yakar et al. observed increased body weight and body fat percentage, as well 
as reduced glucose tolerance as measured by a glucose tolerance test in OVX rodents [22]. 
Additionally, Kumagai et al. found that OVX rodents do not demonstrate changes in body weight 
or fat, but were insulin resistant as measured by a euglycemic hyperinsulinemic clamp [43]. 
Skeletal muscle also becomes insulin resistant with a loss of estrogen as demonstrated by 
reduced insulin-stimulated glucose uptake [40, 43, 45, 46]. When OVX rodents are placed on a 
high-fat diet (HFD), metabolic dysfunction is further exacerbated. A high caloric diet for 10 
weeks in OVX rodents leads to further increased body weight, body fat percentage, insulin 
resistance as demonstrated by an insulin tolerance test, glucose tolerance test and high leptin 
levels [22].  Later studies found similar results in the exacerbation of weight gain, food intake 
[37] and insulin resistance with a HFD [35, 36].  
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Reduced metabolic signaling in muscle from OVX rodents may account for reduced 
insulin sensitivity in skeletal muscle as well as systemically. Muscle from OVX mice 
demonstrate reduced phosphorylation of AMP-activated protein kinase (AMPK), which is a 
master regulator of energy homeostasis that activates glucose and fatty acid oxidation pathways 
[47, 48]. Additionally, changes in glucose uptake following a loss of estrogen may be due to 
reduced insulin signaling. Phosphorylation of Akt [40, 48] and IRS-1 in the insulin signaling 
pathways of skeletal muscle are reduced following ovariectomy [48]. Insulin receptor substrate 1 
(IRS-1) is a signaling adaptor protein, and Protein kinase B (Akt) is a serine/threonine-specific 
protein kinase. Both are required for the insulin-induced translocation of Glut4 to initiate glucose 
uptake. Although ovariectomies in rodents reduce skeletal muscle glucose uptake, the majority 
of studies have found no difference in Glut 4 protein content [37, 46, 49]. Reduced translocation 
of Glut4 may be more important than changes in protein content with a loss of estrogen [46].  
Along with reductions in insulin signaling, other metabolic signaling pathways are also 
reduced in OVX rodents. Whole-body oxygen consumption is decreased in OVX rodents [38, 
40], which may be due to downregulated fatty acid oxidation signaling pathways specifically in 
skeletal muscle. Impaired fatty acid oxidation signaling in skeletal muscle of OVX rodents 
includes various aspects of fat metabolism including fatty acid uptake, β-oxidation, and 
mitochondrial biogenesis. Specifically, Campbell et al. found that a loss of circulating estrogen 
resulted in a 20% reduction of CPT-1 and β-HAD activity in skeletal muscle [50]. CPT-1 
(carnitine palmitoyltransferase) is a protein that transports fatty acids into the mitochondria for 
oxidation, and β-HAD (β-3-hydroxyacyl-CoA dehydrogenase) is a part of the β-oxidation 
pathway. Additionally, Kamei et al. found reduced expression of genes (PPARGC1A, ERR1, 
ACO, and MCAD) which regulate fatty acid oxidation in OVX rodents. [34]. Other studies have 
found similar reductions in PGC-1α and downstream effector TFAM gene expression with 
ovariectomy [48, 51]. PGC-1α is a transcriptional coactivator that activates various energy 
metabolism pathways and is a master regulator of mitochondrial biogenesis. Therefore, 
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reductions in this protein as well as reductions in numerous aspects of fatty acid oxidation can 
have dramatic negative effects on skeletal muscle metabolism.  
Along with reductions in expression of various metabolic genes, mitochondrial function is 
also impaired in skeletal muscle with ovariectomy. Skeletal muscle oxygen consumption was 
observed to be reduced in OVX rodents in multiple studies [33, 41, 51]. Cavalcanti-de-
Albuquerque et al. found that by 8 weeks post-ovariectomy, there was a decrease in PGC-1α 
expression and oxygen consumption of lipid substrates in both fast and slow twitch muscle. 
Additionally, these animals had higher lactate levels following intense exercise, possibly 
indicating increased reliance on glycolysis [41]. Studies have also observed increased H202 
generation [51] in ovariectomized rodents, and a reduction in uncoupling protein expression 
which can worsen damage from oxidative stress [48, 51]. Deficiencies in mitochondrial oxygen 
consumption, mitochondria content, and increased oxidative stress contribute to skeletal muscle 
metabolic dysfunction in ovariectomized rodents.  
In addition to the abovementioned mitochondrial deficiencies observed with a loss of 
estrogen, impaired mitochondrial function with ovariectomy may also be due to alterations in 
mitochondrial dynamics. Capllonch et al. demonstrated that OVX decreases expression of 
proteins which regulate mitochondrial dynamics including MFN1, MFN2, and DRP1 [51]. 
Mitofusin (MFN) proteins are mitochondrial fusion proteins, while Dynamin-related protein 1 
(DRP1) is a mitochondrial fission protein. Activation of DRP1 and fission of the mitochondria is 
required for mitophagy (degradation of dysfunctional mitochondria). Mitophagy is important in 
the maintenance of high mitochondrial quality, and reduction in mitophagy may contribute to 
obesity and diabetes [52, 53].  
A loss of mitochondrial function and accumulation of dysfunctional mitochondria can 
significantly contribute to impaired lipid handling in various tissues, including skeletal muscle. 
OVX mice have increased skeletal muscle triglyceride (TAG) storage [33, 34, 40, 42], and 
diacylglycerol (DAG) content [40], a lipid intermediate, which contributes to insulin resistance. 
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Additionally, Camporez et al. observed increased protein content of lipid transporter proteins, 
CD36 and FABP. CD36 (also called FAT, fatty acid translocase) and FABP (fatty acid binding 
protein) both transport fatty acids across the cell membrane to be oxidized or stored [40]. 
Together these studies demonstrate that ovariectomy reduces fatty acid oxidation, impairs 
mitochondrial function, and increases fatty acid uptake which may contribute to increased lipid 
accumulation and insulin resistance that are seen following a loss of estrogen. 
Many studies investigating ovariectomy or estrogen treatment fail to evaluate or consider 
fiber type in their results looking at skeletal muscle. It is important to remember when 
investigating skeletal muscle-specific differences that findings may vary depending on the fiber 
type investigated. These muscle types are described as oxidative (type I), glycolytic (type II), or 
intermediate (type IIa) based on the metabolic pathways they typically depend on. Oxidative 
muscle fibers contain more mitochondria, higher levels of myoglobin, and increased expression 
of oxidative enzymes. Glycolytic muscles contain few mitochondria and greater expression of 
glycolytic enzymes. The effect of ovariectomy on skeletal muscle outcomes may be due to a 
fiber type shift, since diabetic patients demonstrate a shift in their muscle types to more type II 
fibers [54, 55].  
1.2.3 ERα as a Primary Mediator of Metabolic Function  
The physiological action of estrogen is mediated through two receptors, ERα and ERβ. In 
the classical genomic pathway, ligand-bound estrogen receptors bind to estrogen response 
elements (ERE) in gene promoters and regulate transcription [56]. In non-classical pathways, 
ERs (such as GPER) localize at the plasma membrane and are activated/inhibited via post-
translational modifications through various signaling pathways [57-60]. Although ovariectomized 
models have been valuable in investigating metabolic dysfunction with a loss of estrogen, 
estrogen receptor knockout models have also provided important evidence towards how 
estrogen acts metabolically. ERα is the primary player in the protective metabolic effects of 
estrogen, and this was clearly demonstrated in ERα-/- models. Male and female ERα-/- mice 
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exhibit increased adiposity and insulin resistance, as well as impaired fatty acid β-oxidation and 
accumulation of bioactive lipids in muscle [61, 62]. Additionally, muscle-specific ERα-/- mice also 
demonstrate impaired glucose homeostasis, diminished skeletal muscle oxidative metabolism, 
and impaired mitochondrial function and dynamics [63]. Furthermore, ERα pharmacological 
activation improves metabolic homeostasis through increasing insulin sensitivity [64], oxygen 
consumption and reducing weight gain and fat accumulation [65]. These past studies have been 
imperative in identifying the role of ERα in metabolic homeostasis. Similar studies investigating 
ERβ and metabolism have found that ERβ knockout animals do not have impaired metabolism 
[62, 66, 67]. Additionally, activation of ERβ did not improve skeletal muscle insulin sensitivity like 
activation of ERα [68]. However, one study identified that a reduction in ERβ may protect 
against insulin resistance and glucose intolerance in adipose tissue [67]. Future studies are 
needed to identify the role of ERβ in regulating metabolism. 
Further investigation into estrogen-agonists has also advanced the field’s understanding 
of possible treatment methods. Hormone replacement therapy is known to alleviate conditions in 
postmenopausal women such as osteoporosis and cardiovascular disease [69]. In the Women’s 
Health Initiative clinical trials, hormone therapy alleviated some of these conditions, but they 
also observed increased risk of breast cancer, stroke, and heart disease [70]. Since this trial, 
there has been a demand for the development of safe estrogen mimetic compounds. There is 
promise in the use of selective estrogen receptor modulators (SERMs) and tissue-selective 
estrogen complexes (TSEC) which have agonistic and antagonistic activity in a tissue-specific 
manner [71-74]. Kim et al. demonstrated that the SERM bazedoxifene (BZA) alone, and in 
combination with conjugated estrogen, acts in an ERα specific manner to improve glucose 
tolerance and energy expenditure in mice [73] and can reduce body weight gain caused by 
ovariectomy [75-77]. Further studies continue to investigate SERMs [74, 78, 79] and will be 
important in the treatment of postmenopausal women.  
10 
 
1.2.4 Exercise as Treatment for Postmenopausal Women 
Exercise is a possible treatment approach to prevent or reverse metabolic dysfunction 
that occurs during menopause [80-83]. With a loss of estrogen, rodents and humans 
demonstrate a loss of physical activity [31, 32, 84-87]. This is consistent in ERα knockout mice 
[88]. This reduction in physical activity is also extended to exercise capacity. Ovariectomized 
[31, 32, 84, 89] and ERα knockout animals (unpublished observations) demonstrate a reduction 
in capacity to perform exercise. This may be partially due to the observed impairments in whole-
body and skeletal muscle oxygen consumption and skeletal muscle mitochondrial function [33, 
38, 40, 41, 51, 61]. Impairments in exercise capacity, whole-body oxygen consumption and 
skeletal muscle metabolism imply that with a loss of estrogen it’s likely that there is also a 
reduction in cardiorespiratory fitness. Cardiorespiratory fitness, or aerobic capacity, describes 
the ability of the body to deliver and utilize oxygen in peripheral tissues. Low aerobic capacity is 
a prominent risk factor for metabolic dysfunction, hypertension, cardiovascular disease and 
mortality [90-93].  
Work from the laboratory of Vieira-Potter recognizes the importance of aerobic capacity 
in protection against ovariectomy-induced insulin resistance. Her laboratory has studied the 
relationship between aerobic capacity and a loss of estrogen by using a rat that is artificially 
selected for low and high running capacity. These rodents are only exposed to a single running 
test to separate them into two groups; the low and high capacity runners (LCR and HCR) [94]. 
These animals have stark differences in aerobic capacity. Her laboratory found that rodents with 
enhanced aerobic capacity are protected against increased adipose accumulation and the 
development of insulin resistance with ovariectomy [95]. This is most likely due to the enhanced 
energy expenditure [95] and increased insulin-stimulated glucose uptake  in skeletal muscle and 
adipose tissue in the rodents with high aerobic capacity [96]. Additionally, Park et al. from the 
Vieira-Potter laboratory investigated if rodents with low aerobic capacity could improve their 
metabolic homeostasis following ovariectomy by using exercise. They found that exercise 
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increased insulin sensitivity, energy expenditure, mitochondrial content and skeletal muscle 
AMPK activation in both low and high-capacity runners following ovariectomy [97]. 
Although aerobic capacity has very strong genetic components [94], low physical activity 
also reduces aerobic fitness, which demonstrates that participation in exercise can improve 
one’s aerobic fitness [98]. This observation is supported by a study from Earnest et al. and 
others which demonstrate that aerobic exercise protects postmenopausal women from the 
development of metabolic syndrome and is dose-dependent [80, 99]. In addition to aerobic 
capacity, some past studies have shown that exercise training can improve metabolism in 
ovariectomized rodents [32, 100-106]. Researchers have found that exercise can mitigate some 
of the loss in metabolic function that occurs with a loss of estrogen. Exercise and estrogen act 
similarly to improve whole-body and skeletal muscle metabolism [95, 100, 103, 107-113] 
through improving insulin action, lipid handling, and oxidative capacity and increasing skeletal 
muscle expression of ERα [107, 108, 114]. It is clear from these past studies that reduced 
aerobic capacity contributes to the development of metabolic syndrome in postmenopausal 
women. These studies also demonstrate that exercise should continue to be considered as a 
strong treatment option in postmenopausal women. 
 
1.3 Non-Alcoholic Fatty Liver Disease 
Metabolic disease is very common, and can affect various age-groups, organs, and both 
genders. Fatty-liver, or non-alcoholic fatty liver disease (NAFLD) is the liver component of 
obesity and metabolic disease. As discussed above, skeletal muscle is very important in 
glucose homeostasis through its regulation of glucose uptake and the effects of skeletal muscle 
mitochondrial function on whole-body metabolic homeostasis. The liver is also very important in 
systemic metabolism, specifically through its regulation of gluconeogenesis. With metabolic 
disease, the liver displays various metabolic defects including mitochondrial dysfunction, excess 
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lipid storage, inflammation, and insulin resistance all of which contribute to systemic 
dysregulation of glucose.  
1.3.1 Prevalence and Diagnosis of NAFLD 
NAFLD is defined as excessive accumulation of fat in the liver which is also referred to 
as steatosis. This is defined by the liver triglyceride content as being more than 5 % of liver 
weight [115]. Currently, it is estimated that 34% of the general population and 75-100% of obese 
and extremely obese individuals have NAFLD [116, 117]. Due to this connection, NAFLD 
patients have a high risk of developing hepatic insulin resistance, ultimately contributing to 
hyperglycemia, dyslipidemia (high plasma triglycerides or low HDL cholesterol) and 
development of type 2 diabetes [118, 119]. In about 25% of cases increased hepatic lipid 
storage in NAFLD can progress on to more severe liver disease called non-alcoholic 
steatohepatitis (NASH) [120]. In addition to steatosis, hepatocyte ballooning, lobular 
inflammation, and mega mitochondria development occur with NASH. This can further progress 
to fibrosis, cirrhosis and hepatocarcinoma [120]. 
NAFLD is diagnosed by identifying the presence of steatosis through imaging or 
histology, along with reports of little alcohol consumption by the patient [121].  Imaging 
procedures can be used (CT scans, magnetic resonance imaging, or transient elastography) to 
detect steatosis and possible fibrosis [122]. The severity of NAFLD is difficult to diagnose since 
liver biopsy is the best method to properly assess the liver histologically [123]. NAFLD is further 
diagnosed through abnormal liver tests (such as serum aspartate transaminase (AST) and 
alanine transaminase (ALT), and hepatitis blood tests) and the presence of metabolic risk 
factors [124]. A NAFLD fibrosis score can be determined by a physician through identifying a 




1.3.2 Development and Treatment of NAFLD 
Liver fat accumulation occurs when fatty acid uptake, storage, and de novo lipogenesis 
is greater than fatty acid oxidation and efflux of lipids. Inflammation, lipotoxicity, oxidative stress, 
mitochondrial dysfunction, endoplasmic reticulum stress, and variations in the microbiome are 
all part of the development of NAFLD. NAFLD is thought to progress to liver injury through the 
“two hit hypothesis”. The first hit is the excessive accumulation of triglycerides in the liver. The 
second hit involves oxidative stress, mitochondrial dysfunction and inflammation which can lead 
to further liver damage [126]. Kupffer cells are macrophages that are present in the liver through 
which inflammatory signaling and cytokine production are mediated [127, 128]. Alterations in 
cytokine production (e.g. TNFα, IL6) and hormone production (e.g. adiponectin) in obesity 
contribute to NAFLD development [129, 130]. The main therapeutic approach to treat NAFLD is 
a change in lifestyle. Modest weight loss around 5-10% can decrease inflammation, improve 
steatosis and histology, and lower risk of disease progression [131].   
Research from Dr. Thyfault and others has shown that exercise training can effectively 
prevent and treat hepatic steatosis [132-134]. Exercise and intrinsic aerobic capacity in rodents 
leads to improved hepatic mitochondrial function (enzyme activities, respiration and oxidation) 
[135, 136]. Fitness and physical activity are also important in improving liver function and 
decreasing hepatic triglyceride levels in humans [137-139]. For example, Kantartzis et al. 
observed that high cardiorespiratory fitness increased effectiveness of a lifestyle intervention to 
decrease liver fat [137]. Exercise also alleviates insulin resistance and NAFLD symptoms in 
patients independent of weight loss [140]. Further research is necessary to allow clinicians to 
prescribe exercise that is specific to treat NAFLD and NASH. 
Surgery and pharmacological interventions are also possible treatments for NAFLD. 
Bariatric surgery improves glucose production, insulin sensitivity, fibrosis, and decreases VLDL-
TG secretion [141, 142]. It is also common for physicians to prescribe insulin sensitizers, 
hypertension medication, or medication to manage dyslipidemia such as statins [143]. 
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Pharmacological agents to treat weight loss have not been adopted as the main therapeutic 
approach by physicians due to negative side effects or overall little improvement [144-146]. 
There has also been a push for researchers and clinicians to find an effective and safe 
medication that can treat NAFLD and NASH directly. Various pharmacological compounds have 
been investigated to treat NASH such as vitamin E [147], pentoxifylline [148] and 
ursodeoxycholic acid [149]. Although there are many promising pharmacological agents 
currently being studied, as of yet there is no medication that can effectively and safely treat 
NAFLD and NASH. 
1.3.3 Relationship between NAFLD and Metabolic Syndrome 
It is continually debated whether NAFLD is a cause or result of whole-body metabolic 
dysfunction and insulin resistance. Increased steatosis is often associated with whole body 
insulin resistance [150-152]. However, there are also numerous animal studies that have found 
a disconnect between steatosis and insulin resistance, in which they found the presence of 
steatosis but not insulin resistance [153-155]. In fact, in some cases steatosis is a mechanism 
which guards the liver from the development of insulin resistance through protection from 
exposure to lipid intermediates [156, 157].  
Still, other studies have found a strong connection between steatosis and insulin 
resistance. Insulin resistance may precede and encourage the development of fatty liver 
through promoting lipid synthesis.  In healthy individuals, insulin activates hepatic insulin 
signaling and suppresses gluconeogenesis [158].  Insulin resistance in the liver decreases the 
liver’s ability to regulate gluconeogenesis, therefore hyperglycemia is increased 
[130].Throughout the progression of insulin resistance, there is increased production of insulin 
by the pancreas in an attempt to compensate for the decreased whole-body sensitivity and 
increased circulating glucose. Hyperinsulinemia stimulates de novo lipogenesis and triglyceride 
synthesis pathways in the liver, therefore contributing to the development of fatty liver [159].  
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NAFLD also contributes to systemic insulin resistance and may occur before insulin 
resistance. One of the liver’s primary functions is to maintain whole-body metabolic homeostasis 
through regulation of blood sugar levels. Increased storage of hepatic lipids due to increased 
circulation of free fatty acids in obesity leads to dysfunction in hepatic glucose and fatty acid 
metabolism [159]. Current evidence suggests that dyslipidemia also induces insulin resistance 
through increased intracellular generation of toxic lipid intermediates (DAG, ceramides) which 
can inhibit insulin signaling and activate inflammation [160, 161]. Due to the shared 
mechanisms in the development of NAFLD and metabolic syndrome, it is nearly impossible to 
discern the cause and effect [162] and mostly likely both equally contribute to whole-body 
metabolic dysfunction. 
One commonality in the pathogenesis of NAFLD and insulin resistance is inflammation. 
One main pro-inflammatory pathways that is activated in various tissues with insulin resistance 
and NAFLD progression is the JNK pathway [163, 164]. The cJUN-N-teriminal-kinase (JNK) 
pathway is not only an important player in the cell stress response, but it also is a major 
signaling transducer in obesity and insulin resistance [165]. Deletion of certain isoforms of JNK 
protects mice from insulin resistance induced by a HFD [166], and increased JNK activity occurs 
in in the muscle, liver, and adipose tissue of various rodent models of obesity [163]. Specifically, 
JNK decreases insulin signaling in skeletal muscle through inhibiting the insulin receptor 
substrates 1 and 2 [165, 167]. Additionally, JNK promotes the increase in production of pro-
inflammatory cytokines from adipose tissue in obese individuals [168]. JNK also contributes to 
the development of NAFLD through dysregulating hepatic mitochondrial function.  Fatty acid 
oxidation and respiration are impaired while reactive oxygen species (ROS) production in the 
liver is increased with the activation of JNK [163, 166, 167, 169, 170]. JNK is an essential part of 
the molecular mechanism connecting obesity to metabolic syndrome and NAFLD. 
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1.3.4 Liver Metabolism and Mitochondrial Dysfunction 
The liver is a central organ involved in metabolic regulation. The liver takes up free fatty 
acids from circulation, oxidizes free fatty acids and glucose, synthesizes triacylglycerol, 
produces ketones, and assembles and secretes VLDL particles. Dysregulation in any of these 
pathways can lead to metabolic dysfunction and NAFLD [171].  In simple terms, NAFLD occurs 
when there is an imbalance in hepatic fatty acid input (uptake, storage, and synthesis) and fatty 
acid output (oxidation and secretion). Dysfunction of various hepatic metabolic pathways leads 












Figure 1. Hepatic metabolic dysfunction contributes to excess lipid accumulation. 
Physical inactivity and overnutrition/obesity lead to dysfunction in various hepatic metabolic 
pathways. Reduced lipid efflux or oxidation, and increased uptake, storage, and de novo 
lipogenesis together result in the excess accumulation of lipids in the liver. This leads to further 












Uptake of Fatty Acids 
Hepatocytes obtain fatty acids from various sources:  lipolysis of adipose tissue to non-
esterified fatty acids (NEFA), hydrolysis of chylomicrons coming from the gut, de novo 
lipogenesis, and hydrolysis of intracellular triglycerides. Fatty acids that are absorbed in the gut 
are converted to chylomicrons as triacylglycerol (TAG) and sent out to the lymphatic system. 
Chylomicrons reach the liver through the hepatic artery and portal vein and lipoprotein lipase 
(LPL) at the hepatic cells releases the non-esterified fatty acids. In order for lipids to enter the 
liver, membrane transport proteins such as cluster of differentiation 36 (CD36), fatty acid binding 
protein (FABP), fatty acid transport proteins (FATP), and calveolin proteins allow for fatty acids 
to cross the hepatic membrane [171, 172]. Once inside the cell, long chain fatty acids are 
activated to acyl-coenzyme A (CoA) through attachment of a CoA by acyl-CoA synthetases 
[173]. Long-chain fatty acids and fatty acyl-CoAs bind to fatty acid binding protein (FABP) or 
acyl-CoA synthetases (ACS) and then are carried to various cellular compartments.   
Fatty acid transporters have a role in the development of NAFLD. FAT/CD36 is a fatty 
acid transporter that is expressed in tissues that are important for lipid metabolism [174]. Obese 
rodent models have increased hepatic steatosis and expression of CD36 [151, 175]. 
Additionally, FATP5 [176] and FABP1 knockout animals [177, 178] exhibit protection from 
triglyceride storage and NAFLD. The repetitive mechanisms that are used by liver cells to take 
in lipids from circulation demonstrates the dependence of the liver on free fatty acids, and the 
complications in studying how fatty acid uptake contributes to NAFLD.  
Triglyceride Storage 
Fatty acyl-CoAs are mainly shuttled to three different pathways which are oxidation, 
ketogenesis, or conversion into triglycerides. Fatty acids that are converted to triglycerides can 
be stored or secreted as very low-density lipoproteins. The main pathway for construction of 
triglycerides from fatty acyl-CoAs is the glycerol-3-phosphate pathway [179]. There are 
numerous enzymatic steps for acyl-CoA to be combined with glycerol-3-phosphate (G3P) and 
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form TAG. The production of phospholipids is also intertwined in this pathway, and some of the 
intermediates produced can branch off for phospholipid production. The steps happen 
sequentially through 1) glycerol-3-phosphate acyltransferase (GPAT), 2) 1-acylglycerol-3-
phsophate acyltransferase (AGPAT), 3) the phosphatidate phosphatase action of lipin, and the 
4) giacylglycerol acyltransferase (DGAT) enzyme [180].  
Increased activation of the TAG synthesis pathway may lead to the development of 
NAFLD. This phenomenon has been demonstrated in studies utilizing models which target TAG 
synthesis enzymes such as GPAT and DGAT. Knockout rodent models for GPAT1 are 
protected from steatosis and insulin resistance in the liver when placed on a high-fat diet [181], 
and have decreased circulating TAG and VLDL cholesterol [182]. Also, GPAT1 liver 
overexpression results in the reversal of these measures [183], which further supports the 
importance of GPAT1 for fatty liver disease development. The last step for TAG synthesis 
involves diacylglycerol acyltransferase (DGAT) 1 or 2 which adds an acyl moiety to glycerol 
[184]. Silencing or knockout of each isoform has been demonstrated to reduce steatosis and 
increase oxidation and energy expenditure [185, 186].  It is clear that DGAT proteins are 
involved in the development of NAFLD, although the consequences of increased lipid storage 
are still unclear. Monetti et al demonstrated that DGAT1 and 2 overexpression in the liver 
resulted in increased steatosis without changes in insulin signaling [153]. These results 
demonstrate the need for further investigation into whether steatosis is deleterious or protective 
in different situations. 
Lipid Export 
In addition to intracellular storage, triglycerides are released as VLDL from the liver in 
order to deliver cholesterol and triglycerides to peripheral tissues. VLDL particles contain 
apolipoprotein B (ApoB), cholesterol esters and triglycerides and are formed by the microsome 
triglyceride transfer protein (MTTP). In NAFLD patients, increased VLDL is formed due to 
increased adipose tissue lipolysis, hepatic de novo lipogenesis and increased circulating 
20 
 
triglycerides [187, 188]. Additionally, patients with NAFLD have decreased high density 
lipoprotein cholesterol (HDL) [189]. HDL particles aid in the elimination of excess cholesterol in 
the body by transporting it to the liver for conversion into bile. VLDL-TG secretion is one 
mechanism to decrease triglyceride storage in the liver, however in patients with NAFLD 
increased VLDL synthesis is unable keep up with intracellular triglyceride production and fatty 
acid uptake [190]. In patients with NAFLD, increased VLDL secretion rate eventually plateaus, 
which may contribute to the progression and worsening of NAFLD [190].  
Fatty Acid Oxidation 
 The liver requires a high amount of energy to perform its tasks. One of the liver’s main 
functions is to maintain systemic metabolic homeostasis. During fasting or exercise, the liver 
maintains metabolic homeostasis by breaking down glycogen stores through glycogenolysis and 
also making glucose through gluconeogenesis. Hormonal signals regulate these processes. For 
example, glucagon increases hepatic gluconeogenesis in times of low glucose, and insulin 
decreases hepatic gluconeogenesis in the liver [191]. Metabolites that come from skeletal 
muscle and adipose tissue (lactate, amino acids, NEFAs and glycerol) are taken up in the liver 
and used for gluconeogenesis.  
The liver mainly fuels its processes through oxidizing fatty acids. However, during 
hyperglycemia, the liver uses glucose as its main fuel source through glycolysis and oxidative 
phosphorylation, stores glucose as glycogen, and also converts glucose into fatty acids through 
de novo lipogenesis. In times of lower glucose, the liver depends on fatty acids. Once inside 
hepatocytes, fatty acyl-CoAs are primarily oxidized in the mitochondria. Fatty acyl-CoAs enter 
the mitochondrial matrix through conversion to acyl carnitines by CPT-1 and 2 and are 
transported across the mitochondrial membrane by carnitine-acylcarnitine translocase. This is 
the rate limiting step of fatty acid oxidation (FAO) [192]. Once inside the lumen, the acyl-
carnitines are once again converted to acyl-CoAs and subsequently go through β-oxidation. 
Overexpression of CPT-1 in hepatocytes results in increased FAO and lower TAG storage 
21 
 
[193]. In NAFLD patients, CPT gene expression is decreased in the liver compared to people 
without NAFLD [194], thus ultimately reducing fatty acid oxidation.   
β-oxidation involves multiple enzymatic steps including dehydrogenation, hydration, and 
cleavage. These reactions are catalyzed by four enzymes; acyl-CoA dehydrogenase, 2-enoyl-
CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase, and 3-ketoacyl-CoA thiolase. This process 
shortens a fatty-acyl CoA by two carbon units each cycle. The product of carbon cleavage is the 
molecule acetyl-CoA which thus can enter (tricarboxylic acid cycle) TCA cycle for complete 
oxidation and production of reducing equivalents that enter the Electron Transport Chain.  
Peroxisomes and microsomes also partially contribute to fatty acid oxidation. About 10% 
of β-oxidation occurs in peroxisomes, although this is increased with high lipid exposure [195]. 
Peroxisomal β-oxidation breaks down very long chain fatty acids and dicarboxylic acid and is 
different from mitochondrial oxidation due to the production of H2O2 in the first dehydrogenation 
step [196]. Peroxisomes do not contain an electron transport chain and send intermediates to 
the mitochondria. In situations with high lipid exposure, like obesity and NAFLD, peroxisome 
function is important for the cell to face metabolic challenges. One study found that when β-
oxidation is not functional in hepatic peroxisomes, there is increased steatosis [197]. 
Additionally, overutilization of peroxisomal β-oxidation, which occurs with high lipid exposure 
and metabolic disease, leads to H2O2 production from peroxisomes and can further contribute to 
NAFLD progression. Microsomal oxidation (ω-oxidation) also contributes minimally overall fatty 
acid oxidation, but like peroxisomal oxidation, microsomal oxidation is increased with high lipid 
exposure and produces H2O2 [171, 194].  
Ambiguities exist as to how the rate of hepatic fatty acid oxidation may be linked to 
obesity and NAFLD. Previous research has shown that a reduction of β-oxidation enzymes in 
the livers of rodents leads to increased steatosis in the liver [198], and an increase in β-
oxidation enzymes reduces hepatic steatosis [199]. However, a reduction of FAO does not 
seem to contribute to the development of NAFLD in humans.  With increased exposure to fatty 
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acids in NAFLD, initially there are increased levels of fatty acid oxidation [200, 201]. However, 
other deficits are seen in the mitochondria such as morphological changes, impaired ATP 
production and also increased ROS production [202-205]. Although oxidation may not be 
reduced as NAFLD develops, there could be uncoupling of fatty acid oxidation process to ATP 
production which would alter overall hepatic metabolism. Additionally, impaired FAO may 
depend on the stage of NAFLD, and only occur in later stages or with a transition to NASH. 
Ketogenesis 
Ketogenesis is another important process for the liver to maintain metabolic 
homeostasis. Ketone bodies (acetoacetate and β-hydroxybutyrate) are primarily produced in 
liver mitochondria and production is increased when glucose is not available or following 
exposure to high levels of fatty acids [206]. Ketones are formed from acetyl-CoA produced 
during β-oxidation of fatty acids. Various studies have observed an increase, no change, or a 
decrease of hepatic ketogenesis during metabolic disease [207-214]. However, not all of these 
studies specifically identified the stage of liver disease development, which may contribute to 
the inconsistencies. When studies have focused on the specific stage of liver disease, more 
clarity is achieved. In early insulin resistance or hepatic steatosis either no change or an 
increase of ketogenesis has been observed [207-212]. This is similar to what has been 
observed with changes in fatty acid oxidation in early liver metabolic dysfunction [207, 211-214]. 
With more advanced liver disease and the development of NASH, studies have found a 
reduction in ketogenesis [209, 210, 212].  
Ketogenesis is often considered as a fuel source for other tissues, but this process is 
important for the maintenance of hepatic metabolic function as well. About two-thirds of the 
fat that comes to the liver is converted into ketones [215], therefore the majority of fatty acid 
oxidation is directed to ketogenesis [211]. When the liver is exposed to excess lipids it may 
compensate by  increasing ketogenesis, β-oxidation, and cholesterol export to prevent excess 
hepatic lipid accumulation and lipotoxicity. As liver disease advances towards steatohepatitis, 
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increased lipid storage and lipotoxicity occurs since these pathways cannot compensate for the 
increased influx of substrates due to lipid oversupply. Therefore, ketogenesis can be a 
mechanism of lipid disposal, and dysfunction in this pathway could promote the development of 
NAFLD into NASH. Cotter et al. studied the importance of ketogenesis to prevent steatohepatitis 
by using a knockout mouse for mitochondrial 3-hydroxymethylglutaryl CoA synthase 
(HMGCS2), which is the first enzyme involved in ketogenesis. On a chow diet, these animals 
had increased gluconeogenesis and de novo lipogenesis, but when placed on a HFD they 
developed severe inflammation and impaired gluconeogenesis [209]. This study demonstrated 
that even in non-fasting conditions ketogenesis is critical for normal metabolic flexibility in the 
liver.  
De Novo Lipogenesis 
In addition to transporting lipids across the hepatic membrane, the liver also synthesizes 
lipids through de novo lipogenesis. Acetyl-CoA can be made from citrate, a TCA cycle 
intermediate. This process is enhanced with increased TCA cycle flux, such as in times of 
increased energy intake or with dysregulation of lipid or glucose metabolism [187, 188]. Acetyl-
CoA is then targeted for de novo lipogenesis through conversion to malonyl-CoA by acetyl-CoA 
carboxylase (ACC). The final enzyme in this pathway, fatty acid synthase (FAS), converts 
malonyl-CoA and NADPH into palmitic acid.  
Numerous enzymes and transcription factors regulate the rate of lipogenesis including 
SREBPs, ChREBPs, LXR, FXR and PPARs [171, 194, 216, 217]. Hormones such as insulin 
and glucagon control de novo lipogenesis through regulation of these enzymes. Specifically, 
insulin increases expression of ACC and SREBP-1c, and activates insulin signaling (Akt, 
mTOR) to promote de novo lipogenesis [217, 218]. Glucagon, which increases in times of 
fasting and exercise, opposes insulin action through activating AMPK. AMPK is a master 
regulator of energy homeostasis. Glucagon stimulates AMPK to increase hepatic fatty acid 
oxidation and inhibit de novo lipogenesis [219, 220].  
24 
 
De novo lipogenesis intermediates also regulate fatty acid oxidation through inhibiting 
entrance of fatty acids into the mitochondria. McGarry et al. showed that malonyl-CoA is an 
inhibitor of CPT-1 [221]. Thus, ACC, which converts acetyl-CoA to malonyl-CoA, not only 
increases de novo lipogenesis but also decreases CPT-1 activity [222]. This system allows for 
an extra layer of regulation and rapid shifts in substrate utilization. Dysregulation of hepatic de 
novo lipogenesis is mainly due to increased expression of lipogenic genes in patients with 
metabolic disease [159, 194, 223]. This increase in de novo lipogenesis can further promote 
insulin resistance and elevate circulating LDL cholesterol and triglyceride [224].   
Role of the Mitochondria 
Mitochondria produce energy through the oxidation of nutrients and are highly important 
to the function of hepatocytes. Hepatocytes have a higher density of mitochondria and faster 
mitochondrial turnover than skeletal muscle [225]. Substrates come to the mitochondria mainly 
from glucose and lipid metabolism. Glucose is broken down into pyruvate which is brought into 
the mitochondria and converted to acetyl-CoA for entrance into the TCA cycle. Fatty acids are 
brought to the mitochondria, are broken down in β-oxidation and then enter into the TCA cycle 
also as acetyl-CoA. Mitochondria are the coordinators of hepatic lipid metabolism and as a 
result, mitochondrial dysfunction is considered central to the development of NAFLD [226, 227]. 
The mechanisms leading to mitochondrial dysfunction in NAFLD are complex and can be 
attributed to abnormalities in FAO (as mentioned above), mitochondrial biogenesis, and 
oxidative phosphorylation. Mitochondrial dysfunction can alter lipid metabolism, increase ROS 
production and lipid peroxidation, and increase the release of cytokines [228]. All of these 
factors contribute to liver disease development.  
Various animal models have provided evidence linking hepatic mitochondrial dysfunction 
to NAFLD and insulin resistance.  Rector et al. studied a rodent model with a genetic defect in 
mitochondrial β-oxidation to determine the effect on insulin action. This impairment of β-
oxidation resulted in hepatic steatosis and systemic insulin resistance [229].  In a separate 
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study, Rector et al. showed that in a hyperphagic rodent model (obese OLETF rat) a reduction 
of fatty acid oxidation and mitochondrial content occurs before the progression to hepatic 
steatosis or insulin resistance [230]. These studies demonstrate the importance of mitochondrial 
dysfunction in animal models that develop hepatic steatosis and insulin resistance.   
The Electron Transport Chain and ATP Production 
Reducing equivalents (NADH and FADH2) are produced throughout fatty acid and 
glucose metabolism for entrance into the electron transport chain. NADH and FADH2 donate 
electrons to the ETC which is coupled to proton pumping into the inner membrane space. 
Pumping of protons across the inner mitochondrial membrane creates an electrochemical 
gradient. Energy is produced through coupling electron transfer down the ETC to ATP 
production. ETC complex function can be compromised with metabolic dysfunction [228, 231]. 
Past research has demonstrated reduced activity of ETC complex proteins with NAFLD and 
NASH in rodent and human studies [203, 232, 233]. This can lead to impaired mitochondrial 
function through reduced respiration. Mechanisms behind ETC dysfunction are still being 
studied, but may be due to increased reactive oxygen species production [234, 235].   
Oxidative stress  
Increased ROS production occurs with NAFLD and can lead to damage of cellular 
components including mitochondrial DNA, lipids, and protein [232, 235]. Reactive lipid 
mediators can be formed with oxidative stress, such as 4-hydroxy-2-nonenal (4HNE), which can 
increase uncoupling of the mitochondria thus reducing ATP production [236]. ROS can also 
further increase cytokine production in the liver such as TNFα which can activate apoptotic 
pathways [237]. In addition to increased oxidative stress, patients with NAFLD have an impaired 
antioxidant capacity through a reduction in antioxidant enzyme activity such as glutathione and 
SOD [238]. Low antioxidant capacity increases mitochondrial damage and impairs the liver’s 
ability to face a metabolic challenge. Various antioxidants have been investigated as treatments 
for NAFLD. Vitamin E is an antioxidant which was shown to improve fibrosis and progression of 
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liver disease, although this treatment had negative side effects and is only recommended for 
NASH [147, 239]. Other antioxidations that possibly prevent the ROS damage are betaine [240], 
N-acetylcysteines [241], vitamin C [242], and resveratrol [243]. Although there have been 
promising results in studies investigating these antioxidants, they have had minimal success in 
clinical trials or require further study. 
Biogenesis and Degradation of Mitochondria 
Mitochondria are able to adjust to their environment and high or low substrate exposure 
through regulating ATP production, mitophagy, and apoptosis [244]. They achieve this through 
rapid post-translational modifications and cellular signaling, as well as longer term adjustments 
in mitochondrial mass. Mitochondrial content is maintained through the balance of biogenesis 
and mitophagy [245]. Mitochondrial biogenesis is regulated by transcription factors and 
signaling proteins. PGC-1α is a transcriptional coactivator and one of the master regulators for 
mitochondrial biogenesis. This coactivator is important in tissues with high oxidative capacity 
such as skeletal muscle, liver, and brown adipose tissue [246, 247]. 
 PGC-1α interacts with transcription factors such as PPARα and TFAM to activate target 
gene expression thus increasing not only mitochondrial biogenesis, but also fatty acid oxidation, 
ketogenesis, and ATP production [248, 249]. PGC-1α also increases gluconeogenesis through 
activating the transcription factors hepatocyte nuclear factor 4a (HNF4a) and FoxO1 [250]. 
Rapid cell signaling through AMPK occurs with exercise and fasting which then increases 
mitochondrial gene expression through AMPK-mediated phosphorylation of PGC-1α [251]. 
Additionally, exercise and fasting increases NAD+ levels which leads to activation of Sirtuin 1 
(SIRT1). SIRT1 is an energy sensor and deacetylase, which deacetylates PGC-1α and FOXO1, 
further activating them in order to increase gluconeogenesis and fatty acid oxidation. These 
pathways are highly important in mitochondrial biogenesis and function, and can prevent excess 
liver triglyceride storage [252].  
Mitochondrial biogenesis is also balanced with mitochondrial degradation through mitophagy. 
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With metabolic dysfunction, mitochondrial morphology is altered as evidenced by a loss of cristae 
and swelling of the mitochondria [202, 205]. This has been observed with obesity, type 2 diabetes 
[253, 254] and NAFLD [202, 205]. One reason behind the accumulation of damaged mitochondria 
is an impairment in mitochondrial dynamics. Mitophagy occurs to remove damaged mitochondria 
through the cellular degradation process of autophagy. This is achieved through the sequestration 
of damaged mitochondria in autophagosomes which then fuse with lysosomes for degradation 
[255]. Mitophagy requires a coordinated interaction of various autophagy proteins (ex: LC3II, p62) 
and mitophagy proteins (ex: Parkin, BNIP3, Mfn2, DRP1) which aid in the fission, targeting, and 
tethering of the mitochondria to the autophagosome. Impaired mitophagy can result in retention 
of damaged, ROS producing mitochondria [53, 256]. The balance between mitophagy and 
mitochondrial biogenesis may be essential in lipid metabolism [257-261]. More investigation 
needs to be done to understand the role of mitophagy in the development of NAFLD. 
Impairments in an overall cellular degradation pathway, autophagy, also seems to 
contribute to NAFLD. Autophagy defects have been implicated in liver disease, 
neurodegenerative diseases, and metabolic syndrome [52]. Additionally, autophagy has been 
demonstrated to be important for maintenance of glucose homeostasis [262]. Autophagy can 
specifically degrade lipids through lipophagy. Thus, impaired autophagy could cause lipid 
accumulation in NAFLD [259]. Novel strategies to protect cellular and mitochondrial integrity and 
function through upregulation of mitophagy and autophagy could be effective in treating and 









1.4 Heat Shock Proteins 
1.4.1 Role of Heat Shock Proteins 
Growing evidence suggests the heat shock response and/or heat shock proteins (HSPs) 
could play an important role in preventing insulin resistance and the development of type 2 
diabetes. HSPs are a highly conserved family of proteins best identified for their role as 
molecular chaperones [263]. They play a critical role in maintaining cellular function via 
regulation of protein folding and degradation. Not surprisingly, changes in their expression 
profile and cellular localization are linked to numerous disease states. Several studies suggest 
that induction, transcription and translation of these cytoprotective HSPs decline with chronic 
disease such as NAFLD [264], Huntington’s Disease [265], and type 2 diabetes [266]. 
Conversely, induction and/or transgenic overexpression of HSPs results in ample metabolic 
benefit in animal models of obesity/metabolic disease [266-272]. Less clear, however, are the 
factors that regulate HSP expression in the pathological development of metabolic disease. In 
particular, very little is known regarding skeletal muscle HSP expression levels throughout the 
progression of obesity, insulin resistance and type 2 diabetes.   
As skeletal muscle is the primary tissue responsible for insulin-stimulated glucose 
uptake [273], many researchers have investigated changes in skeletal muscle HSP expression 
during obesity, insulin resistance and type 2 diabetes. Skeletal muscle HSP72 (a member of the 
HSP70 family expressed in animals) expression is inversely related to body fat percentage and 
blood glucose in healthy subjects [270, 274]. Additionally, both HSP72 mRNA and protein 
expression are significantly reduced in the skeletal muscle of type 2 diabetic patients and 
subjects with insulin resistance [266, 275-278]. Therefore, many have asserted that HSP72 
expression levels are tightly correlated to adiposity and decrease through the progression from 
obesity to metabolic disease (i.e. insulin resistance and type 2 diabetes).  
Interestingly, multiple studies using animals fed a HFD highlight that this relationship is 
much more complex. For instance, investigations in primates and rodents show that short-term 
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high-fat feeding (16- and 6-12 weeks, respectively) results in hallmark symptomology of insulin 
resistance but does not significantly reduce skeletal muscle HSP72 expression [267, 268, 271, 
279-281]. In fact, HSP72 expression may increase after short-term high-fat feeding, suggesting 
a possible compensatory response to combat metabolic dysfunction [279, 280]. However, long-
term high-fat feeding (6 years) appears to cause significant reductions in skeletal muscle 
HSP72 expression similar to the phenomenon described in type 2 diabetics [279]. Therefore, it 
is possible that skeletal muscle HSP72 expression can be characterized as an inverted 
parabolic relationship wherein initial increases in skeletal muscle HSP72 combat metabolic 
dysfunction, but these levels will eventually peak and decline depending on the severity and 
time spent under metabolic strain (Solid green line, Figure 2). 
  Discrepancies in the data regarding skeletal muscle HSP72 reductions during obesity, 
insulin resistance and type 2 diabetes may also be due to the model being used and the muscle 
type analyzed. For example, investigations reporting significant reductions in HSP72 expression 
during obesity, insulin resistance and type 2 diabetes primarily analyzed the vastus lateralis 
muscle from human subjects [275-278]. Alternatively, primate and rodent investigations 
observing no significant reductions in HSP72 expression in response to short-term high-fat 
feeding analyzed the biceps femoris, soleus, and extensor digitorum longus muscles [267, 268, 
271, 279-281]. Thus, it is also possible that organismal differences and/or muscle fiber type 
differences, variations in muscle oxidative capacity, and muscle size could contribute to inter-
study data variations. It is critical that future investigators address these inconsistencies when 
designing studies to address the role of HSP72 expression in metabolic disease. A greater 
understanding of the regulation of skeletal muscle HSPs during insulin resistance will allow 
future development of targeted therapies to maintain and even increase HSP expression to 




Schematic depicting the timeline of metabolic disease from insulin resistance to type 2 diabetes. 
Insulin resistance can persist for 10-12 years prior to clinical diagnosis of type 2 diabetes, a time 
period that represents an increased risk for cardiovascular disease, obesity and type 2 diabetes. 
During insulin resistance, insulin secretion (red line) from pancreatic beta cells increases in an 
effort to maintain blood glucose (blue line). Insulin sensitivity declines (yellow line) resulting in a 
gradual increase in blood glucose and the development of type 2 diabetes. Insulin resistance 
represents a window of time when progression towards more severe metabolic disease can be 
prevented by lifestyle interventions like diet and exercise. HSPs are robustly induced by 
exercise and HSP72 mRNA and protein expression are significantly reduced in the skeletal 
muscle of type 2 diabetic patients. However, very little is known about HSP expression patterns 
and regulation during insulin resistance. We hypothesize that HSP72 expression, in particular, 
may demonstrate an inverted parabolic relationship wherein initial increases in HSP72 combat 
metabolic dysfunction, but expression levels eventually peak and decline with disease severity 
and time spent under metabolic strain (solid green line). Exercise and heat treatment represent 
potential targeted therapies that could maintain and even increase HSP expression to prevent 
metabolic disease (dashed green line).  




1.4.2 HSP Mechanisms of Action in Insulin Resistance 
The complex, integrative and multi-organ nature of the HSP response makes the 
identification of specific mechanisms of action difficult. For instance, the most widely known 
HSP, HSP72, has varying roles and mechanisms of action in heart muscle, skeletal muscle, 
adipose tissue and the liver. Recent studies suggest decreasing inflammation, improving 
mitochondrial function/oxidative capacity, and maintaining proteostasis could be viable 
mechanisms of action for HSPs in metabolic tissues. 
Anti-Inflammatory Properties of HSP72.    
The ability of HSPs to decrease inflammation has centered on the proinflammatory 
protein JNK. Importantly, JNK activation is increased with the progression of insulin resistance 
and diabetes [166, 167, 169, 170, 282, 283], while HSP72 expression is correspondingly 
decreased [266, 275, 284, 285]. This inverse relationship between JNK activation and HSP 
expression also occurs during the progression from non-alcoholic fatty liver disease (NAFLD) to 
non-alcoholic steatohepatitis (NASH) [264]. This relationship is of no coincidence. JNK 
activation indirectly inhibits HSP expression by maintaining heat shock factor 1 (HSF1), the 
primary HSP transcription factor, in its inactive monomeric state [286, 287]. Beyond inactivation 
of HSF1 and HSP expression, there are other downstream targets of JNK that potentiate insulin 
resistance. 
JNK is thought to drive insulin resistance through inhibitory phosphorylation of insulin 
receptor substrate1- (IRS-1), a key protein in the insulin signaling cascade [288]. In addition, 
JNK can downregulate peroxisome proliferator-activated receptor α/fibroblast growth factor 21 
(PPARα/FGF21) signaling in hepatocytes, leading to reduced fatty acid oxidation and the 
development of insulin resistance [289]. JNK activation also inhibits mitochondrial respiration, 
increases ROS production and causes apoptosis [290-294]. Previous studies suggest that 
HSP72 induction directly inhibits JNK activation, thereby improving insulin sensitivity and 
glucose tolerance at both skeletal muscle-specific and systemic levels [266, 267, 269, 295, 
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296]. For example, work by our laboratory has demonstrated that in vivo heat treatments 
decrease JNK activation in skeletal muscle of aged and HFD-fed rats [268, 297]. 
Pharmacological activation of HSP72 also causes reduced JNK activation in skeletal muscle 
and liver [267, 295]. Finally, overexpression of HSP72 in skeletal muscle decreased JNK 
activation in mice fed a HFD and was associated with beneficial metabolic outcomes [266]. In 
each instance, lowering of JNK activation resulted in improvements in insulin sensitivity and 
glucose tolerance, highlighting the importance of this HSP-mediated mechanism for insulin 
action.  
HSP72 is proposed to regulate JNK activation through multiple mechanisms including 
direct inhibition via protein-protein interaction with JNK [298], and/or inhibition of upstream JNK 
signaling pathways [299, 300]. Evidence also exists suggesting that activation of HSP72 in the 
liver may decrease inflammation independent of JNK inhibition.  Specifically, pharmacological 
activation of HSP72 decreases steatosis without decreasing JNK activation in HFD-fed rodents 
[301]. Although no change in JNK activation was observed, increased HSP72 expression 
resulted in inhibition of tumor necrosis factor α (TNFα) in the liver of rodents fed a HFD.  
HSP72 may also play additional anti-inflammatory roles extracellularly or via localization 
in macrophages. For instance, HSP72 decreases during NAFLD progression in human Kupffer 
cells, which are liver-specific macrophages [264]. Interestingly, heat-induced upregulation of 
HSP72 in Kupffer cells coincides with suppression of TNFα [302, 303]. Additionally, in myeloid 
cells, JNK activity is considered essential for activation of macrophages and a release of pro-
inflammatory cytokines [168, 304]. The ability of extracellular HSP72 to inhibit pro-inflammatory 
cytokine release from macrophages, lymphocytes, and other immune cells [305-310] could be 
critical in decreasing local inflammation and attenuating the development of insulin resistance.  
HSP72 Regulation of Mitochondrial Integrity and Function.  
Mitochondrial dysfunction is a primary contributor to the development of metabolic 
disease and is therefore a possible target for therapy [311-313]. Our laboratory and others have 
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shown that heat treatment improves skeletal muscle mitochondrial function by improving fatty 
acid oxidation [268], increasing mitochondrial enzyme activity [268, 314, 315], and increasing 
mitochondrial biogenesis [316]. Transgenic overexpression of HSP72 in skeletal muscle also 
increases mitochondrial enzyme activity, mitochondrial content, and endurance running capacity 
[266, 269]. Thus, it is possible that the beneficial mitochondrial adaptations stemming from heat 
treatment are a result of HSP72 induction.  
 HSP72 induction may mediate mitochondrial improvements by regulating mitophagy, 
the targeted degradation of mitochondria through autophagy.  For instance, mice lacking 
skeletal muscle HSP72 demonstrate a reduced ability to degrade mitochondria through 
mitophagy [317]. Additionally, these mice exhibit enlarged, dysmorphic mitochondria with 
reduced muscle respiratory capacity and increased lipid accumulation. Thus, activation of 
HSP72 may improve mitochondrial quality by enhancing the degradation of dysfunctional 
mitochondria.  
Heat Shock Transcription Factor Regulation of Oxidative Capacity.  
One of the most important heat shock response functions in metabolic tissue may 
actually lie upstream of HSP72. HSP72 overexpression leads to an increase in mitochondrial 
content, oxidative capacity, and insulin sensitivity [266, 311-313, 318]. Similarly, the absence of 
HSP72 expression results in mitochondrial dysfunction and insulin resistance [317]. In addition 
to increasing HSP72 content, and thereby the ability to enhance mitochondrial quality control, 
exercise also increases peroxisome proliferator-activated receptor γ coactivator 1-α (PGC1α) 
expression [319-321]. PGC1α is the primary transcriptional coactivator for mitochondrial 
biosynthesis [322, 323]. Interestingly, recent investigations reveal that the upstream regulatory 
elements of the PPARGC1A gene contain a heat shock element (HSE) binding sequence. This 
HSE sequence provides a docking site for the primary HSP transcription factor, heat shock 
factor 1 (HSF1). Indeed, chromatin immunoprecipitation analyses show that HSF1 and PGC1α 
co-occupy the HSE sequence on the promoter of the PPARGC1A gene [324]. Through a myriad 
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of HSF1 activation and knockdown experiments, the Mueller lab provides compelling evidence 
that HSF1 is a primary regulator of mitochondrial biogenesis, enzymatic function, and whole-
body metabolism [324, 325]. These data exemplify the elegant coordination of HSF1 
downstream targets (i.e. HSPs and PGC1α) in regulating mitochondrial biogenesis, quality 
control, and enzymatic function under conditions of metabolic demand and/or chronic disease. 
Importantly, future research is needed to delineate the specific contributions of varying 
downstream HSF1 targets, as well as potential direct effects of HSF1 itself, with regard to 
metabolic outcomes. This information, combined with a greater understanding of HSP 
mechanisms of action in metabolic tissue, may provide novel therapeutic targets to ameliorate 
metabolic dysfunction. 
1.4.3 Exercise-Induced HSP Response 
Exercise is a primary treatment modality for patients exhibiting symptoms of metabolic 
dysfunction. Specifically, regular exercise training is known to decrease metabolic and 
cardiovascular disease risk factors in patients suffering from obesity and metabolic dysfunction 
[326, 327].  Exercise is also a potent inducer of HSP expression [328], with HSP72 showing the 
most robust and consistent upregulation with exercise. HSP72 induction via heat treatment, 
pharmacologic intervention, and transgenic overexpression result in metabolic effects similar to 
exercise in models of obesity and insulin resistance [266-268, 297, 328]. Thus, exercise-
induced HSP72 expression may contribute to the beneficial metabolic effects observed with 
exercise training. There is already a significant amount of information available about exercise 
and HSPs, however little is known regarding the role of exercise-induced HSP72 expression in 
treating metabolic disease. 
Complexity of the Exercise HSP Response 
The direct cause of exercise-induced HSP upregulation, primarily HSP72, remains 
unknown. It is hypothesized that a variety of biochemical, metabolic, and/or physical stressors 
may stimulate HSP72 expression post-exercise. For instance, common challenges to tissues 
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during exercise such as mechanical stress, acidosis, hypoxia, ischemia, reactive oxygen 
species formation, and calcium signaling changes are shown to independently cause HSP 
induction [329-337]. Additionally, increased metabolic stress via depletion of bioenergetic 
substrates (i.e. glycogen) is shown to potentiate exercise-induced HSP72 expression [338]. A 
similar potentiation effect is observed when exercise bouts are completed in a hot environment, 
but this effect is blunted in a cold environment [339]. Thus, it appears that elevations in HSP72 
expression post-exercise are not a result of one, but many physiologic stressors associated with 
exercise.  
 Adding complexity is the understanding that exercise-induced HSP expression is training 
modality, intensity, and duration dependent. In skeletal muscle, elevations in HSP72 expression 
occur with both aerobic and resistance training [340, 341]. Importantly, HSP72 expression is 
dependent on exercise intensity. For instance, HSP72 expression displays a positive 
relationship with exercise intensity during both aerobic and resistance training [338, 340, 342, 
343]. This relationship also exists when comparing exercise intensity and metabolic outcomes 
[344], supporting the potential contribution of HSP72 induction to the metabolic benefits 
associated with exercise.  
HSP72 expression also varies based on the duration of the training regimen (i.e. acute 
versus chronic training).  Acute exercise bouts cause dramatic elevations in HSP72 within 24h 
[340], while chronic training regimens typically result in minimal elevations in HSP72 post-
exercise [336]. Similarly, untrained subjects exhibit lower basal HSP72 expression and a higher 
degree of change in HSP expression post-exercise compared to fit subjects [336, 345].  The 
minimal degree of change in HSP72 expression observed during long-duration training 
protocols and in fit subjects is likely a result of adaptation to exercise. This phenomenon, 
referred to as the repeated bout effect [346, 347], is exemplified by the lack of potentiated HSP 
induction in recurring exercise bouts (specifically HSP72 and HSP27) [348]. However, cessation 
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of exercise in trained subjects will cause basal HSP expression to return to levels comparable to 
those observed pre-exercise [349].  
Aerobic Capacity and Exercise Training Impact HSP Expression and Induction.  
Recently, our lab has published data suggesting that intrinsic aerobic capacity, or the 
ability of the body to take up and utilize oxygen, is coupled to HSP induction and metabolic 
flexibility [271]. Low aerobic capacity increases susceptibility to developing metabolic 
dysfunction. Importantly, it is estimated that 50-70% of one’s aerobic capacity is attributable to 
inheritable traits [350]. This genetic/phenotypic phenomenon is exemplified by rodent models 
selectively bred for high-capacity or low-capacity running (HCR and LCR respectively) [351]. 
Specifically, these models have drastic differences in susceptibility to metabolic complications 
[136, 352-354].  For instance, the HSP72 response is blunted in LCR rodents after heat 
treatment and they require the heat intervention to maintain metabolic flexibility/protection when 
acutely challenged with a HFD [271]. Conversely, HCR rodents maintain the ability to 
upregulate HSP72 expression in skeletal muscle via heat treatment and display metabolic 
flexibility/protection independent of intervention when metabolically challenged. These data 
suggest that intrinsic aerobic capacity is coupled to the HSP72 response in skeletal muscle and 
that these two factors are primary contributors to whole-body metabolic health. As mentioned, 
unfit subjects with metabolic dysfunction, and most likely low aerobic capacity, have markedly 
low levels of HSP72 expression compared to healthy controls [266, 275, 276]. Thus, chronic 
exercise may restore basal HSP72 expression levels to that of healthy subjects. The restoration 
of basal HSP72 expression via exercise may directly impact organ-specific insulin sensitivity. 
Tissue-Specific HSP Expression and Induction.  
As mentioned, exercise increases skeletal muscle HSP72 expression. However, the 
levels of both basal HSP72 expression and exercise-induced HSP72 expression are dependent 
on muscle fiber type. For instance, muscles predominantly composed of type I fibers have 
higher basal HSP72 expression compared to muscles composed of type II fibers [355, 356]. 
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Furthermore, the magnitude of HSP72 upregulation is much greater in type II muscle fibers 
post-exercise compared to type I fibers [340, 357]. This may explain the intensity dependent 
increases in HSP72 expression post-exercise, as higher intensity activities cause the 
recruitment of fast-twitch muscle fibers, resulting in a greater overall change in HSP72 
expression. As type II muscle fibers are inherently glycolytic and have a high dynamic range of 
HSP72 expression, it invites the possibility that the positive metabolic effects seen with HSP72 
overexpression may be primarily mediated by changes in type II fast-twitch muscles.  
 Exercise is also known to increase HSP72 expression in the liver, kidney, lungs, heart, 
and brain [358-360]. Interestingly, exercise also results in the release of extracellular HSPs 
(eHSPs) from the hepatosplanchnic viscera and brain into circulation [338, 361], and other 
potential sites of origin include epithelial cells [362] and immune cells [363, 364]. During states 
of metabolic dysfunction, HSP72 expression in the liver is of primary concern due to the organ’s 
role in maintaining whole-body metabolic homeostasis. Pharmacologic HSP72 induction in the 
liver is shown to improve insulin sensitivity and glucose tolerance in models fed a high-fat diet 
[295]. This protective effect may stem from the enhancement of HSP72-mediated mitochondrial 
quality control and the restoration of the insulin signaling pathway in hepatocytes - both of which 
occur with exercise and HSP72 upregulation in skeletal muscle. Thus, exercise-induced HSP72 
expression in the liver may act to restore liver insulin sensitivity by mechanisms similar to those 
observed in skeletal muscle. However, future studies are needed to confirm this notion. 
 
1.5: Research Questions 
It is established that HSPs regulate metabolic function systemically and specifically in 
skeletal muscle. Impaired HSP induction in skeletal muscle has been studied in the prevention 
of obesity and diabetes, although information is still needed about the role of HSPs in the 
prevention of other metabolic-related conditions. Two specific metabolic conditions which may 
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be prevented by activating HSPs are metabolic syndrome in postmenopausal women and 
NAFLD.  
Past studies using ERα-/- mice have aided in the understanding of metabolic dysfunction 
with a loss of estrogen in postmenopausal women. However, the metabolic characteristics have 
not been characterized in the ERα-/- rat model which could further define estrogen-mediated 
metabolic regulation. Additionally, the effect of these metabolic changes on exercise capacity 
has not been investigated. We aim to identify the metabolic effects of ERα-/- in a rat model, as 
well as investigate how ERα loss affects exercise capacity. One past study in ERα-/- mice has 
identified an impairment of HSP induction [88].  We also aim to investigate heat shock protein 
expression in the rat ERα-/- model and speculate on a connection between ERα and the heat 
shock response. These data could identify similarities between ERα and HSP regulation of 
metabolism and identify future areas of investigation for an ERα/HSP72 mechanism in skeletal 
muscle. 
Past studies looking at the metabolic effects of heat shock proteins have mainly focused 
on the skeletal muscle. Due to the need for new therapeutic approaches for NAFLD, identifying 
the role of HSP72 in hepatic metabolism is necessary. We aim to identify the hepatocyte-
specific role of HSP72 in preventing hepatic steatosis. Additionally, we have previously 
observed the induction of HSPs in the liver [268], and others have identified hepatic HSP72 
induction with exercise [358, 365, 366]. However, HSP72 induction across multiple exercise 
modalities and with acute and chronic exercise has not been established in the liver. We aim to 
investigate HSP72 induction with acute and chronic exercise and identify how this could 
improve hepatic metabolic function. These studies will widen the understanding of HSP72 in the 
development of metabolic dysfunction and advance its use as a therapeutic target in various 













































Postmenopausal estrogen deficiency increases the risk for metabolic syndrome, obesity, 
and type 2 diabetes. Estrogen treatment improves metabolic function in postmenopausal 
women, and estrogen receptor α (ERα) is thought to be the primary player in these protective 
metabolic effects through increasing insulin sensitivity and mitochondrial function. However, 
there is not still not a complete understanding of ERα-mediated mechanisms. Additionally, the 
effect of these metabolic deficits on exercise capacity have not been elucidated. The purpose of 
this study was to investigate the impact of ERα loss on whole-body metabolic homeostasis, 
skeletal muscle metabolic pathways, and exercise capacity in a rat model. 14 wk-old female 
Wildtype (WT) and ERα knockout (ERα -/-) rats were exercised to exhaustion and one week later 
a glucose tolerance test was performed. At sacrifice, body weight and adipose tissue depot 
weights (subcutaneous, retroperitoneal and periuterine) were measured. Adipocyte cell size, 
mitochondrial protein content, and heat shock protein expression were assessed by 
immunohistochemistry and western blot, respectively. Intramuscular triglyceride storage was 
also assessed. ERα deficient rats had increased body weight and subcutaneous adipose tissue 
mass compared with WT rats. Although there was no increase in retroperitoneal adipose tissue 
mass, adipocyte size was increased in ERα deficient rats. HOMA-IR values were increased in 
ERα -/- rats indicating increased insulin resistance. ERα deficiency also decreased exercise time 
to exhaustion when compared with WT rats. Mitochondrial proteins Complex IV, cytochrome c, 
and mitochondrial regulator peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC-1α) were significantly decreased in white gastrocnemius muscle, and intramuscular 
triglyceride storage was increased in red and slightly increased in white gastrocnemius skeletal 
muscles from ERα deficient rats. Lastly, basal HSP72 and HSP60 protein expression was 
reduced in white gastrocnemius of ERα -/- rats. Our data demonstrate the potential regulatory 
role of ERα to enhance aerobic capacity and improve energy metabolism both systemically and 
in skeletal muscle in a rat model. Exercise as treatment in postmenopausal women has the 
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potential increase aerobic capacity and preserve high metabolic function. Increased aerobic 
capacity maintains heat shock protein and mitochondrial protein expression in skeletal muscle, 
thus acting to prevent metabolic disease.  
Key words: Estrogen receptors, postmenopausal women, skeletal muscle, insulin 













































Metabolic syndrome is a cluster of metabolic disorders affecting 23% of adults [367]. 
This condition puts people at risk for other health problems such as cardiovascular disease, 
type 2 diabetes, and stroke [367]. Post-menopausal women are at increased risk for metabolic 
syndrome and type 2 diabetes. With a loss of circulating estrogen, women experience weight 
gain, reduced insulin sensitivity, and decreased energy expenditure and fat oxidation [14, 368-
372]. Ovariectomized rodents demonstrate similar metabolic impairments such as weight gain, 
increased adiposity, and insulin resistance [15, 33, 34, 38]. Estrogen treatment improves insulin 
sensitivity and glucose tolerance [43, 44, 373-375]. This is due, in part, to estrogen activation of 
skeletal muscle metabolic pathways at a cellular level [40, 376-379].   
Estrogen acts through two receptors in tissues, estrogen receptor (ER)α and ERβ. The 
receptor that is most responsible for the metabolic actions of estrogen is ERα, which is highly 
expressed in insulin sensitive tissues [88, 380]. ERα knockout models have allowed for deeper 
understanding of estrogen-mediated mechanisms. Whole-body ERα ablation in a mouse model 
results in obesity and reduced glucose tolerance [62, 88, 375, 381]. These mice also develop 
skeletal muscle insulin resistance, increased lipid storage, and reduced markers of fatty acid 
oxidation [62, 88, 375]. Additionally, muscle-specific ERα ablation (MERKO) in a mouse model 
results in a similar phenotype of increased adiposity, insulin resistance, and skeletal muscle 
metabolic dysfunction [63]. Ribas et al. found that skeletal muscle mitochondrial dysfunction, 
specifically in the mitochondrial degradation pathway of mitophagy, contributes to increased 
lipid accumulation and impaired oxidative metabolism in MERKO mice [63]. ERα can also be 
activated with pharmacological compounds, which increases insulin sensitivity and energy 
expenditure and reduces weight gain in rodents [64, 65, 77, 382].  Knockout models and ERα 
activation studies have allowed for a better understanding of estrogen regulation of metabolism 
at a tissue and cellular-level, however metabolic characterization has not been done in other 
available ERα-/- species, specifically the rat [383]. Further characterization of the effect of ERα 
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knockout will continue to better define these mechanisms and help identify best treatment 
approaches in postmenopausal women.  
Exercise is one treatment modality which could improve insulin resistance and reduce 
adiposity caused by a loss of estrogen during menopause [80-83]. Past research has shown 
that ovariectomized mice run less than control animals [31, 32, 84], and that whole-body ERα-/- 
mice demonstrate reduced ambulatory movement [88], however exercise capacity in the ERα 
knockout models has not been investigated. The purpose of this study is to 1) characterize 
metabolic dysfunction in the ERα-/- rats and 2) identify the impact of ERα loss on exercise 
capacity. Our results demonstrate that ERα-/- rats have whole-body and skeletal muscle-specific 
metabolic deficits including a reduction in expression of mitochondrial proteins and regulators. 
Additionally, a whole-body loss of ERα results in reduced exercise capacity. These findings 
identify other pathways through which ERα could act in skeletal muscle. This study also 
identifies that a loss of ERα negatively impacts the ability for rodents to tolerate a metabolic 
stressor such as exercise.  
 
2.3 Methods 
Experimental Animals. Twelve-Fifteen week-old female Wildtype (WT) and ERα-/- rats 
were from the laboratory of Dr. Michael Soares and Dr. MA Karim Rumi [383]. They were 
housed in a temperature-controlled facility (22 ± 2˚C) with 12:12 h light:dark cycles. Animals 
were allowed ad libitum access to water and were fed a standard chow diet (Envigo TekLad 
8604). Following an overnight fast, animals were anesthetized with pentobarbital sodium and 
tissues dissected for experimental procedures. All protocols were approved by the Animal Care 
and Use Committee of the University of Kansas Medical Center. 
Glucose tolerance test. One week prior to sacrifice, both WT and ERα-/-  animals went 
under an intraperitoneal glucose tolerance test (IPGTT). Following an overnight fast, rats were 
anesthetized with an intraperitoneal injection of pentobarbital sodium (2.5 mg/100 g body 
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weight) and injected with a glucose load of 2 g/kg body wt. Tail blood was removed every 30 
min and glucose levels were assessed using a glucometer and test strips (Accu-Chek Active, 
Roche Diagnostics, Indianapolis, IN, USA). Blood was allowed to clot for 30 min on ice, spun at 
3,000 g for 60 min at 4˚C, and serum was drawn off and frozen at -80˚C. Serum was analyzed 
for concentration of insulin using an insulin ELISA (Alpco, Salem, NH, USA).  
Immunohistochemistry adipose tissue. Retroperitoneal adipose tissue (rpWAT) was fixed 
overnight in 4% paraformaldehyde, placed in 70% ethanol for 48-72 hr, processed and paraffin 
embedded. Ten μM sections were places on slides and subsequently hematoxylin and eosin (H 
& E) stained. Images were taken on a Nikon 80i microscope and images were quantified using 
Image J. 
Glucose Transport. Insulin-stimulated glucose transport into extensor digitorum longus 
(EDL) and soleus muscle was determined as previously [268, 297, 384, 385]. After dissection, 
muscle strips were placed in vials in a shaking incubator (35˚C) for 60 min containing Krebs-
Henseleit bicarbonate (KHB) buffer with 8 mM glucose and 32 mM mannitol. Non-insulin treated 
muscles stayed in the same vials for 30 more minutes. Insulin-treated muscles were transferred 
to new vials for 30 min in the same buffer with the addition of insulin (1 mU/ml) at 35˚C. Muscle 
strips were then transferred to new vials containing 2 ml of KHB and 40 mM mannitol, with or 
without insulin (1 mU/ml) for 10 min at 29˚C. Muscle strips were again transferred to new vials 
containing 2 ml of KHB and 4 mM 2-[1,2-3H] deoxyglucose (1.5 µCi/ml) and 36 mM [14C] 
mannitol (0.2 µCi/ml), with or without insulin (1 mU/ml) for 20 min. During all incubation steps, 
muscle strips were exposed to a gas phase of 95% O2-5% CO2 at 29˚C. Finally, muscle strips 
were blotted, clamp-frozen at -80˚C, and processed for determination of intracellular and 
extracellular accumulation of 2-deoxyglucose. 
Western blots in muscle. Muscles were processed for Western blotting by methods 
previously described [268, 297, 386]. Briefly, muscle was homogenized in a 12:1 (volume-to-
weight) ratio of ice-cold cell extraction buffer (Biosource, Invitrogen) containing 10 mM Tris·HCl 
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(pH 7.4); 100 mM NaCl; 1 mM each of EDTA, EGTA, NaF, and phenylmethylsulfonyl fluoride; 2 
mM Na3VO4; 20 mM Na4P2O7; 1% Triton X-100; 10% glycerol; 0.1% SDS; 0.5% 
deoxycholate; and 250 µl/5 ml protease inhibitor cocktail. Homogenates were rotated for 30 min 
at 4˚C, and then centrifuged for 20 min at 3,000 rpm at 4˚C. The supernatant was removed and 
protein concentration determined by Bradford assay. Samples were diluted in HES buffer and 
Laemmli buffer containing 100 mM dithiothreitol (DDT) (Thermo Scientific, Rockford, IL, USA) 
based on protein concentration to generate samples containing equal concentration of protein. 
Samples were heated in a boiling water bath 5 min. For assessment of mitochondrial 
complexes, samples were diluted in HES buffer, non-reducing lane marker buffer not containing 
DDT (Thermo Scientific, Rockford, IL, USA), and were not boiled. 
Protein (40-80 µg) was separated on SDS-PAGE gels, followed by a wet transfer to a 
nitrocellulose membrane for 90 min at 200 mA. Membranes were blocked in Tris-buffered saline 
(TBS), 0.1% Tween 20 (TBST), and 5% nonfat dry milk or 5% bovine serum albumin (BSA) 
followed by incubation with the appropriate primary antibodies. Following three washes with 
TBST, blots were incubated with an appropriate horseradish peroxidase (HRP)-conjugated 
secondary antibody in TBST 1% nonfat dry milk or BSA at a concentration of 1:10,000 for 1 hr 
at room temperature. Blots were then washed twice with TBST and once with TBS, dried, and 
visualized by enhanced chemiluminescence (ECL). Bands were quantified using Image J or 
Image Lab (Bio-Rad) densitometry. Blots were then stripped for 15-20 min at 55˚C in buffer 
containing 62.5 mM Tris·HCl, 2% SDS, and 100 mM 2-mercaptoethanol and re-probed for α-
tubulin as a loading control. Ponceau (Sigma) was used as a loading control for Complex IV. 
Primary antibodies used included HSP72 (cat no. SPA-810, Enzo Life Sciences, 
Farmingdale, NY), HSP60 (cat no. SPA-807, Enzo Life Sciences), PGC-1α (cat no. 516557, 
Cal-Biochem, Darmstadt, Germany), MitoProfile Total OXPHOS (cat no. ab110413, Abcam, 
Cambrdige, MA), LC3B (cat no. 2775, Cell Signaling Technology, Inc., Danvers, MA), 
cytochrome c (cat no. AAM-175, Enzo Life Sciences), pParkin (phospho s65) (cat no. 
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ab154995, Abcam) Parkin (cat no. sc-32282, Santa Cruz Biotechnology, Dallas, Texas), and α-
tubulin (cat no. ab7291, Abcam). Secondary antibodies used included goat anti-mouse (cat no. 
170-5047, BioRad, Hercules, CA) donkey anti-rabbit (cat no. 711-035-15, Jackson, Immuno-
Research, Inc., West Grove, PA), and goat anti-rabbit (cat no. sc-2004; Santa Cruz 
Biotechnology). 
Exercise capacity. Animals were acclimatized to the treadmill for two days at 12 m/min 
speed. The exercise test on the third day began at a speed of 12m/min at 0% incline. The speed 
was increased every 3 min by 3 m/min until 24 m/min was reached. The exercise was stopped 
when rodents stayed on the shock grid three times for 5 seconds. Exercise time was recorded 
for each animal.  
Triglyceride assay. Intramuscular triacylglycerol concentration was determined based on 
the methods by Frayn and Maycock (123 bob diss). The white and red gastrocnemius muscle 
were homogenized in 3 ml of 2:1 chloroform:methanol, transferred to 13x100 mm borosilicate 
glass tubes, vortexed, and incubated overnight at 4˚C. The following day, 3 ml of 4 mM MgCl2 
was added to each tube, vortexed, and centrifuged at 1,000 g for 1 hr at 4˚C. The bottom 
organic layer (1.5 ml) was drawn off and placed into clean borosilicate glass tubes, allowed to 
dry overnight, reconstituted with 500 µl of ethanolic KOH, and heated at 75˚C for 20 min. 
Following heating, 1 ml of 0.15 mM MgSO4 was added to each tube, centrifuged at 1,000 g for 
1 hr at 4˚C, and supernatant removed and assayed for triglyceride and free glycerol 
concentration using a commercially available colorimetric assay (F6428, Sigma, St. Louis, MO). 
Statistical analyses. Results are presented as mean ± SEM. Statistical significance was 
set at P < 0.05. Analysis was performed using Sigma Plot for Windows, version 12.0 (Systat 
Software Inc., Chicago, IL, USA). Data were compared by unpaired t-test or two-way analysis of 
variance (ANOVA) with Fisher’s post-hoc differences performed where appropriate. Where raw 
values did meet the assumptions of equal variance or normal distribution, values were 




Body weight and adipose changes in the ERα null rat 
Body weight (WT: 307.6 ± 8.2 g, ERα-/-: 428.7 ± 11.3 g) was 39% greater in ERα-/-  rats 
than WT rats (P<0.001, Figure 3A), and energy efficiency was 2.7-fold greater in ERα null 
animals (P<0.05, Figure 3B). This was calculated as the change in body weight divided by 
kilocalories consumed. When normalized to body weight, subcutaneous adipose tissue weight 
(WT: 1299.4 ± 131.3 mg, ERα-/-: 3505.8 ± 466.8 mg) was significantly increased in ERα-/- 
animals (90%, P<0.001, Figure 3C) while other fat pad weights (retroperitoneal and periuterine) 
were not significantly different than the WT animals (not shown). Adipose cell size was also 
evaluated in the retroperitoneal adipose tissue. Although adipose weight was not different, cell 
size of retroperitoneal adipocytes was increased by 62% in the ERα-/-  animals (P<0.05, Figure 
3D and 3E), which is associated with impaired systemic insulin sensitivity [387]. Increased 





















Figure 3.Whole-body ERα -/- in rats results in increased body weight and adipose tissue.  
Body-weight related changes were compared between groups. A) Body weight, B) food 
efficiency C) and subcutaneous adipose tissue (normalized to body weight) were evaluated. 
N=11-14 for body weight and adipose tissue. N=5 for energy efficiency. D) Quantification of 
retroperitoneal (rpWAT) adipocyte size. E) Representative images of rpWAT cross-sections. 
N=5 per group, ~500 cells counted per animal. Values are reported as the mean ± SE.  All were 


















Effect of ERα knockout on insulin resistance  
Fasting blood glucose levels were similar between WT and ERα-/- rats (Figure 4A). 
However, fasting serum insulin levels were 51% greater in ERα rats (P<0.05, Figure 4B). This 
resulted in a 59% greater HOMA-IR in the ERα rats (P<0.05, Figure 4C), suggestive of 
increased insulin resistance. Glucose tolerance was also compared between strains via 
intraperitoneal injection of glucose and tracking of glucose and insulin values over two hours. 
ERα null and WT rats demonstrated similar glucose concentrations throughout the glucose 
tolerance test (Figure 4D) and similar glucose area under the curve (AUC) values (Figure 4F). 
Insulin concentrations were also similar throughout the glucose tolerance test between groups, 
other than a significant increase in insulin values in the ERα-/- at the zero and sixty-minute time 
points (Figure 4E). There was a strong trend for an increased insulin AUC in ERα-/-  rats (45%, 
P=0.07, Figure 4G). This is suggestive of increased insulin secretion in order to maintain similar 
blood glucose values as the WT animals. We also compared insulin-stimulated glucose 
transport in the soleus and EDL between WT and ERα-/- rats. In the soleus muscle, there was no 
significant difference in insulin-stimulated glucose uptake between the WT and ERα-/- animals. 
(data not shown). However, in the EDL muscle, insulin significantly increased glucose transport 




Figure 4. Loss of ERα-/-  leads to systemic and skeletal muscle insulin resistance.  
A) Fasting glucose, and B) insulin were evaluated from serum, and C) HOMA-IR was calculated 
from these values. D) Glucose concentrations, E) insulin concentrations, F) glucose AUC, G) 
and insulin AUC were calculated in response to an intraperitoneal glucose injection. Rats were 
fasted overnight one week prior to sacrifice and were injected with a glucose load of 2 g/kg body 
weight intraperitoneally. Blood glucose was measured prior to, and 30, 60, 90, and 120 min 
following injection using a glucometer. N=6-8 per group. H) Insulin-stimulated glucose uptake 
was evaluated from EDL muscles. Insulin-stimulated glucose uptake was determined by 
incubating muscles in the presence or absence of 1 mU/ml insulin for 20 min. N=8-10 per group. 
Values are reported as the mean ± SE.  All were analyzed by t-test, besides the glucose 









Mitochondrial protein expression  
In order to identify differences in regulation of mitochondrial biogenesis, we measured 
expression of the mitochondrial proteins and regulators. We evaluated changes in peroxisome 
proliferator-activated receptor gamma co-activator-alpha (PGC-1α), electron transport chain 
complexes, and cytochrome C in red gastrocnemius and white gastrocnemius. There was over 
an 85% reduction in PGC-1α (P<0.001, Figure 5A), an 82% reduction in Complex IV (P<0.001, 
Figure 5B), and a 38% reduction in cytochrome c protein content (P<0.05, Figure 5C) in white 
gastrocnemius of ERα-/- rodents. No significant differences were observed in the other 
mitochondrial complex proteins, or in any of the abovementioned proteins in the red 
gastrocnemius muscle (data not shown).  Due to past findings related to mitophagy dysfunction 
in the MERKO mouse  [63], we also evaluated autophagy/mitophagy protein expression in the 
ERα-/- rat. Autophagy is a major cellular degradation pathway, while mitophagy is specifically 
mitochondrial degradation through autophagy. We found a 45% decrease in the expression of 
microtubule-associated protein 1 light chain 3 (LC3-II) with a loss of ERα (P<0.05, Figure 5D). 
LC3 is lipidated to form LC3-II when autophagosomes are forming [388], thus is a marker of 
increased autophagy. We also evaluated Parkin, the E3 ubiquitin ligase which targets 
mitochondria for degradation through mitophagy. Parkin is recruited to the mitochondria and 
activated by Pink1, which phosphorylates Parkin at serine 65 (Ser 65). We observed a 50% 














Figure 5. Mitochondrial protein expression is reduced with a loss of ERα.   
A) Protein expression of PGC-1α, B) Complex IV, and C) cytochrome C, D) LC3II/LC3I E) and 
phosphorylation of the Parkin protein expression were quantified in the white gastrocnemius 
muscle. N=4-5 per group. Values are reported as the mean ± SE.  All were analyzed by t-test. 










Heat shock protein expression and triglyceride storage with a loss of ERα  
Heat shock proteins (HSP), which are cellular chaperone proteins that protect the cell 
from stress, were also evaluated. There was over a 95% reduction in HSP72 (P<0.001, Figure 
6A) and a 25% reduction in HSP60 (P<0.05, Figure 6B) in white gastrocnemius of ERα-/- 
rodents compared to WT. We observed no significant difference in heat shock protein 
expression in the red gastrocnemius. Due to the observed reduction in mitochondrial and heat 
shock protein expression, we also evaluated triglyceride storage in white and red 
gastrocnemius. We observed a trend towards an increase in triglyceride storage in the white 
gastrocnemius (52%, P=0.09, Figure 6C), and a significant increase in triglyceride storage in 





















Figure 6. Basal heat shock protein expression is reduced and triglyceride storage is 
increased in skeletal muscle of ERα-/-  rats.  
A) HSP72 and B) HSP60 protein expression were compared between groups in white 
gastrocnemius. N=4-5 per gruop. C) Triglyceride content in the white gastrocnemius D) and red 
gastrocnemius were also evaluated. N=9-11 per group. Values are reported as the mean ± SE.  
















Effects of ERα knockout on exercise capacity 
Due to changes in mitochondrial and heat shock protein expression, we hypothesized 
that ERα-/- rats would have reduction in exercise capacity. In untrained animals, WT animals ran 
twice as long as ERα-/- animals in an exhaustive exercise treadmill test (P<0.05, Figure 7). This 





















Figure 7. Impaired exercise capacity in the ERα-/- rat.  
After two days of acclimation, untrained WT and ERα-/- animals performed an exhaustive 
exercise bout on a treadmill. N=6-7 per group. Values are reported as the mean ± SE.  Results 
























Various studies have identified ERα as a therapeutic target to prevent the development of 
metabolic syndrome in postmenopausal women. Past studies have discovered mechanisms 
through which ERα acts to maintain skeletal muscle and whole-body metabolism. However, the 
loss of ERα and its effect on metabolism in a rat model had not been characterized. Additionally, 
the effect of ERα loss on exercise capacity was previously unknown. This work further defined 
ERα mechanisms in a new model, and identified the importance of ERα in the ability to perform 
exercise. These results will allow for a better understanding of the development of metabolic 
syndrome with a loss of estrogen which will lead to better treatment approaches.  
In this study, we evaluated exercise capacity in a rat with whole-body knockout of ERα 
through a treadmill exercise test to exhaustion.  We identified that whole-body ERα-/- results in a 
reduced running time compared to WT animals. These results agree with past work which 
demonstrated reduced exercise capacity with a loss of estrogen following ovariectomy [31, 32, 
84, 89]. Ovariectomized rodents also demonstrate reductions in whole-body oxygen 
consumption [38, 40], skeletal muscle fatty acid oxidation and mitochondrial biogenesis 
signaling [34, 48, 50, 51], and skeletal muscle oxygen consumption [33, 41, 51]. The observed 
reduction in exercise capacity in ERα-/- rats may be partially due to the loss of PGC1-α, the 
major regulator of mitochondrial biogenesis, in skeletal muscle. Rodents with mitochondrial 
biogenesis deficiencies through skeletal muscle-specific PGC1-α knockout also demonstrate 
reduced endurance capacity [389]. Additionally, PGC-1α overexpression in the muscle leads to 
enhanced exercise capacity [390, 391]. These past studies demonstrate the importance of 
PGC-1α in exercise capacity. 
Another observation from our study was a reduction in basal HSP72 and HSP60 
expression in the white gastrocnemius muscle in ERα-/- rats. In whole-body ERα-/- mice, Ribas 
et. al did not observe a reduction in basal HSP levels, however they did find a decrease in HSP 
induction with a high-fat diet [88]. Past studies have found that a skeletal muscle HSP 
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expression is associated with exercise and aerobic capacity [271, 392]. Muscle-specific 
overexpression of HSP72 results in a 2-fold increase in endurance exercise capacity and 
increased mitochondrial content and enzyme activity [266, 269]. With the large reductions in 
PGC-1α and HSP72 protein expression in skeletal muscle of ERα-/- rats, it is likely that these 
rodents have reduced aerobic capacity. Cardiorespiratory fitness, or aerobic capacity, describes 
the body’s ability to deliver and use oxygen in peripheral tissues. Low aerobic capacity 
increases susceptibility to developing metabolic dysfunction, hypertension, and cardiovascular 
disease [90-92].  
This study suggests that ERα is important in maintaining aerobic capacity through 
skeletal muscle-specific mechanisms. Reduced aerobic capacity through decreased PGC-1α 
and HSP72 protein expression may be what leads ERα-/- rodents to develop insulin resistance. 
ERα may be acting through heat shock proteins and the mitochondria in order to maintain 
metabolic health. Past studies have shown that exercise training and aerobic capacity improve 
metabolism in ovariectomized rodents [95, 100-105]. Researchers have also identified that 
exercise and estrogen act similarly to improve whole-body and skeletal muscle metabolism [95, 
100, 103, 107-113]. These data imply that exercise should continue to be considered as viable 
treatment modality in postmenopausal women. It would be interesting for future studies to 
investigate the ability of exercise training to improve metabolic parameters in the whole-body 
and muscle-specific ERα-/- rodents. These studies would identify the ability of exercise to 
improve metabolic dysfunction that is seen with a loss of ERα. 
Due to the similarities in metabolic regulation between heat shock proteins and PGC-1α, 
more studies have begun to investigate links between these proteins. A recent study identified a 
heat shock element (HSE) binding sequence upstream from the gene for PGC-1α 
(PPARGC1A). This allows the major HSP transcription factor, heat shock factor 1 (HSF1), to 
bind and regulate PPARGC1A expression [324]. Ma et. al also found that HSF1 and PGC-1α 
bind to each other at the HSE on the PPARGC1A gene. Based on the interaction and 
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coregulatory activity of HSF1 and PGC1-α, and the loss of both PGC1-α and HSP72 in ERα-/- 
rats, it is possible that ERα is also a part of this mechanism. Past studies have identified 
estrogen or estrogen receptor regulation of heat shock proteins in skeletal muscle and 
cardiomyocytes [88, 393-395]. However, the relationship between estrogen receptors and heat 
shock proteins is unclear. Work from our lab did not find a reduction of HSP expression with 
ovariectomy [37], and another study found that estrogen attenuates the HSP72 response after 
exercise [396] . Future studies should investigate the relationship between HSF1 and ERα, and 
the possibility that ERα could be an upstream regulator of HSF1, thus affecting downstream 
expression of PGC1-α and HSP72. 
In addition to investigating exercise capacity in these rodents, we are the first to 
characterize metabolic deficiencies in the ERα-/- rat. Metabolic outcomes can vary between 
species, even between species as close as the mouse and the rat [397-400]. For example, mice 
have a higher basal metabolic rate compared to rats in order to maintain body temperature, as 
well as increased gluconeogenesis and circulation of free fatty acids [397, 400, 401]. These 
differences could cause variability in metabolic outcomes, and highlight the importance of 
characterizing both species in order to further define metabolic molecular mechanisms with a 
loss of ERα. 
 Similar to previous reports in ERα knockout mice, we observed metabolic dysfunction 
with a loss of ERα in the rat model. We observed whole-body changes such as increased body 
weight, adipose tissue, and markers of insulin resistance. We also observed changes in 
mitochondrial protein expression, however, they were unique from past findings [63, 88]. In 
white skeletal muscle, along with a significant decrease the mitochondrial biogenesis regulator 
PGC-1α, we observed a reduction in complex IV, and cytochrome C protein expression. 
Cytochrome c and complex IV are a part of the electron transport chain. There was no change 
in gene expression for these proteins in the MERKO mouse [63], and they were not evaluated in 
the whole-body knockout mice [88]. Although there was no change in protein expression, Ribas 
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et. al did observe a reduction in mitochondrial DNA replication in the MERKO mice [63]. Since 
PGC-1α is a major factor controlling energy homeostasis through regulating mitochondrial 
biogenesis and FAO enzymes, ERα’s metabolic effects could be mediated through this protein. 
Future work investigating changes in mitochondrial content through electron microscopy would 
further define the implications of these protein changes.  
Another major finding by Ribas et. al in the MERKO mice was a reduction in the 
mitochondrial degradation pathway, mitophagy [63]. They found that ERα is important in 
preserving mitochondrial health through maintaining mitochondrial turnover. This is in 
agreement with past studies which have found the importance in autophagy and metabolic 
health [388, 402-404]. In the ERα-/- rats also saw a reduction in autophagy and mitophagy 
proteins through reduced phosphorylation of Parkin and LC3-II protein content in the ERα-/- rats. 
In the mouse model, Ribas et. al did not evaluate Parkin phosphorylation, although they 
observed a reduction in Parkin protein content [63], which we did not observe. They also found 
a reduction in PINK protein content, which phosphorylates and activates Parkin [63]. Based on 
our findings and the findings from the MERKO model, it’s possible that of ERα regulates Parkin 
activation through regulating its phosphorylation. These data along with the other observed 
mitochondrial protein changes confirm that there are mitochondrial deficits in the rat model, 
although they seem to be uniquely regulated compared to the mouse models. 
Another unique perspective from our study is looking at fiber-type specific effects. The 
observed deficits in mitochondrial protein expression, heat shock protein expression, and 
glucose transport were observed in either the EDL or white gastrocnemius muscles, which are 
both mainly comprised of type II muscle fibers [405]. We did not observe these changes in the 
red gastrocnemius which is mainly comprised of type I muscle fibers. However, triglyceride 
storage in red gastrocnemius was significantly increased, and there was a trend towards 
increased storage in the white gastrocnemius. Diabetic patients often undergo a shift from type 
I, oxidative muscle fibers to more type II, glycolytic muscle fibers [54, 55], while the opposite 
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occurs with endurance exercise training [406]. A limitation in this study is that we did not 
evaluate fiber type changes through staining of the myosin heavy chain, however past evidence 
has shown that PGC-1α and HSP72, as well as various mitochondrial proteins, are increased in 
type I, oxidative muscle fibers compared to type II fibers [355, 356, 407-411]. These data 
suggest that with a loss of ERα, there could be a shift away from oxidative characteristics in 
skeletal muscle. These results further suggest that exercise training could prevent some of the 
negative metabolic shifts that occur with a loss of estrogen during menopause.  
In this study, we utilized a whole-body ERα-/- rat to evaluate metabolic changes and 
exercise capacity. Future studies to investigate metabolic characteristics in muscle-specific 
ERα-/- rats would be necessary to further identify skeletal muscle-specific changes with a loss of 
ERα. Additionally, since we utilized a whole-body knockout, it is possible that part of the 
reduction in exercise capacity could be due to a loss of ERα in the brain, leading to reduced 
physical activity [114, 412]. However, due to the metabolic dysfunction and insulin resistance 
seen in both whole-body and MERKO mice in past studies  [62, 88, 375, 381], the skeletal 
muscle metabolic deficits seen in our model could be due to loss of ERα-/- specifically in the 
skeletal muscle. Additionally, past research has shown the importance of skeletal muscle-
specific PGC-1α and HSP72 in exercise capacity [266, 269, 271, 389-392]. Therefore, it is 
conceivable that the skeletal muscle metabolic impairments in the ERα-/- rat also contribute to 
the reduction in exercise capacity. Future studies using a muscle-specific knockout would 
















Figure 8. Systemic and skeletal muscle metabolic dysfunction in the ERα-/- rat.  
Summary of the results describing findings in the ERα-/- rat model. Unique findings are 













Systemic and skeletal muscle metabolic dysfunction in the ERα-/- rat contribute to a 
reduction in exercise capacity. Skeletal muscle reductions in mitochondrial, 
autophagy/mitophagy, and heat shock protein expression likely contribute to this decrease in 
exercise capacity (Figure 8). This study characterized unique metabolic deficits in the whole-
body ERα-/- rat, which identified that basal HSP expression and deficits in mitochondrial proteins 
and regulators could contribute to the skeletal muscle metabolic dysfunction. This suggests that 
therapies that improve skeletal muscle metabolic signaling with a loss of estrogen could be 




























Heat Shock Protein 72 Regulates Hepatic Lipid Accumulation 
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adaptations since publication with permission. Archer, A.E., Rogers, R.S., Von Schulze, 
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Induction of the chaperone Heat Shock Protein 72 (HSP72) through heat treatment, 
exercise, or transgenic overexpression improves glucose tolerance and mitochondrial function 
in skeletal muscle. Less is known about HSP72 function in the liver where an accumulation of 
lipids can result in inflammation, hepatic insulin resistance and Nonalcoholic Fatty Liver Disease 
(NAFLD). The purpose of the current study was 1) to determine whether weekly in vivo heat 
treatment (HT) induces HSP72 protein expression in the liver and improves glucose tolerance in 
rats fed a high-fat diet (HFD) and 2) to determine the ability of HSP72 to protect against hepatic 
lipid accumulation and mitochondrial dysfunction in primary hepatocytes. Male Wistar rats were 
fed a HFD for 15 weeks and were anesthetized and given weekly HT (41°C for 20 min) or sham-
treatments (ST, 37°C for 20 min) for the last 7 weeks. A glucose tolerance test and insulin-
stimulated glucose uptake in skeletal muscle were performed. The impact of an acute loss in 
HSP72 via siRNA on lipid handling and mitochondrial integrity was examined in primary 
hepatocytes. Weekly in-vivo HT increased glucose tolerance and HSP72 protein content and 
triglyceride storage was decreased in skeletal muscle and liver. In primary hepatocytes, 
mitochondrial quality was reduced in the absence of HSP72 while protein expression of PGC-
1α, and mitochondrial ETC complexes were unchanged. Primary hepatocytes also 
demonstrated reduced fatty acid oxidation and increased lipid accumulation following palmitate 
treatment compared with control siRNA-treated primary hepatocytes. This data suggests that in 
vivo HT significantly improves systemic metabolism with robust induction of HSP72 in the liver. 
Acute loss of HSP72 in primary hepatocytes significantly impacts mitochondrial quality and lipid 
handling. These findings suggest future therapies targeting HSP72 in the liver may prevent 
hepatic insulin resistance and NAFLD.  






The heat shock response is a highly conserved defense system to combat cellular and 
oxidative stress [413] comprised of a family of heat shock proteins (HSPs) identified by molecular 
weight [263, 414, 415]. Best known for their chaperone functions, HSPs also have cell signaling 
functions and more recently identified roles in regulation of metabolism [269]. HSP72 is of great 
interest in relation to metabolic disease as it is highly induced in response to stress and with 
endurance exercise [266, 268, 269]. Kurucz et al. first demonstrated that HSP72 expression was 
markedly decreased in skeletal muscle of insulin resistant and type 2 diabetic patients [276]. 
Subsequent studies from our lab and others showed that heat treatment (HT), transgenic 
overexpression of HSP72, and pharmacological induction of HSP72 effectively prevent high-fat 
diet-induced glucose intolerance and skeletal muscle insulin resistance [266-269, 295, 297, 416, 
417]. HSP72 is also important in skeletal muscle mitochondrial function. Loss of HSP72 results in 
retention of dysmorphic mitochondria, but transgenic overexpression of skeletal muscle HSP72 
results in an increase in mitochondrial content and activity of mitochondrial enzymes [269, 317]. 
As a result, HSP72 has a well-established role in regulating glucose homeostasis, insulin 
sensitivity and oxidative capacity in skeletal muscle.  
Two recent studies have indicated a potential role for HSP72 in liver metabolism. Zeng et 
al. demonstrated the small molecule drug matrine, used for treatment of chronic viral infections 
and tumors in the liver, has hepatoprotective effects that involve the activation of HSP72 in the 
liver [301]. In addition, Di Naso demonstrated a correlation between decreased HSP72 protein 
levels in obese patients with progression of insulin resistance and nonalcoholic fatty liver disease 
(NAFLD) [264]. NAFLD is characterized by an excessive accumulation of lipids in the liver that 
ultimately contribute to the development of hepatic insulin resistance, hyperinsulinemia, 
hyperglycemia, and type 2 diabetes. Mitochondria are critical to liver function and considerable 
evidence indicates decreased mitochondrial function contributes to the pathobiology of metabolic 
diseases. However, the mechanisms that govern hepatic mitochondrial function and alter 
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susceptibility for hepatic insulin resistance and steatosis are poorly understood. To date, no 
studies have examined the direct effect of HSP72 modulation on hepatic lipid metabolism.  
The purpose of the present study was two-fold. First, to determine whether in vivo HT 
intervention would sufficiently induce hepatic HSP72 expression and improve insulin sensitivity 
in rats following 8 wk of high-fat feeding. Previously we had noted that 12 wks of weekly HTs in 
conjunction with 12 wk high-fat feeding protected against the development of insulin resistance 
[268], however studies have not investigated the ability of HT to be used as an intervention in 
rodents. Our second aim was to examine the impact of direct HSP72 modulation on primary 
hepatocytes in vitro. Prior studies provide strong evidence that induction of HSP72 increases 
oxidative capacity and mitochondrial function in skeletal muscle. Given that the liver has high 
mitochondrial density and fast mitochondrial turnover [225], it is likely that HSP72 plays an 
important role in maintaining hepatic mitochondrial function. We hypothesize that HSP72 exerts 
beneficial metabolic effects in hepatocytes by supporting fatty acid oxidation and preventing lipid 
storage. Targeting HSP72 could be an effective strategy for reducing hepatic insulin resistance, 
NAFLD and type 2 diabetes.  
 
3.3 Methods 
Experimental animals and in vivo heat treatment. Eight wk old male Wistar rats (~150 – 
180 g each) were purchased from Charles River Laboratories (Wilmington, MA, USA) and 
housed in a temperature controlled facility (22 ± 2˚C) with 12:12 h light:dark cycles. Animals 
were allowed ad libitum access to water. Rats were fed a modified Kraegen high-fat diet (HFD) 
(60% of kilocalories from fat) for 15 wk [268, 418]. During the last 7 wk of the HFD, rats received 
either weekly in vivo heat (HT) or sham treatment (ST, n=9/group). All animals were 
anesthetized with an intraperitoneal injection of pentobarbital sodium (5 mg/100 g body weight) 
prior to ST or HT. HT consisted of lower body immersion in a 42°C water bath to gradually 
increase body temperature to between 41°C and 41.5°C where it was maintained for 20 min. ST 
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consisted of immersion in a 37°C water bath and maintaining body temperature at 37°C for 20 
min [268, 386]. Body temperature was monitored by a rectal thermometer. Following treatment, 
0.5 ml of 0.9% saline was injected intraperitoneally to aid in recovery. Forty-eight h following HT 
or ST, and following a 10-hr overnight fast, animals were again anesthetized with pentobarbital 
sodium and tissues dissected for experimental procedures. All protocols and procedures were 
approved by the Institutional Animal Care and Use Committee of the University of Kansas 
Medical Center. 
Glucose tolerance testing and other blood measures. One week prior to sacrifice, and 48 
h following HT or ST, rats underwent an intraperitoneal glucose tolerance test (IPGTT). 
Following an overnight fast, rats were anesthetized with an intraperitoneal injection of 
pentobarbital sodium (5 mg/100 g body weight) and injected with a glucose load of 2 g/kg body 
wt. Tail blood was removed every 30 min and assessed for blood using a glucometer and the 
manufacturer’s test strips (Accu-Chek Active, Roche Diagnostics, Indianapolis, IN). Blood was 
allowed to clot for 30 min on ice, spun at 3,000 g for 60 min at 4°C, and serum drawn off and 
frozen at -80°C. Serum was analyzed for concentration of insulin using an insulin ELISA (Alpco, 
Salem, NH, USA). Serum triglycerides and NEFAs were also determined by colorimetric assays 
using the manufacturer’s instructions (Cayman Chemical, Ann Arbor, MI and Wako Diagnostics, 
Richmond, VA, respectively).  
Glucose Transport. Insulin-stimulated glucose transport into extensor digitorum longus 
(EDL) and soleus muscle was determined as previously [268, 297, 384, 385]. After dissection, 
muscle strips were placed in vials in a shaking incubator (35˚C) for 60 min containing Krebs-
Henseleit bicarbonate (KHB) buffer with 8 mM glucose and 32 mM mannitol. Non-insulin treated 
muscles stayed in the same vials for 30 more minutes. Insulin-treated muscles were transferred 
to new vials for 30 min in the same buffer with the addition of insulin (1 mU/ml) at 35˚C. Muscle 
strips were then transferred to new vials containing 2 ml of KHB and 40 mM mannitol, with or 
without insulin (1 mU/ml) for 10 min at 29˚C. Muscle strips were again transferred to new vials 
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containing 2 ml of KHB and 4 mM 2-[1,2-3H] deoxyglucose (1.5 µCi/ml) and 36 mM [14C] 
mannitol (0.2 µCi/ml), with or without insulin (1 mU/ml) for 20 min. During all incubation steps, 
muscle strips were exposed to a gas phase of 95% O2-5% CO2 at 29˚C. Finally, muscle strips 
were blotted, clamp-frozen at -80˚C, and processed for determination of intracellular and 
extracellular accumulation of 2-deoxyglucose. 
Adipose tissue imaging. Epididymal white adipose tissue was fixed overnight in 4% 
paraformaldehyde, placed in 70% ethanol for 48-72 h, processed and paraffin embedded. Ten 
μM sections were places on slides and subsequently hematoxylin and eosin (H & E) stained. 
Images were taken on a Nikon 80i microscope and images quantified using Image J. 
Hepatocyte Primary Cell Culture. Hepatocytes from C57Bl6/J mice (~8-20 weeks) were 
isolated by collagenase perfusion. Animals were anesthetized with 1-2 ml of isoflurane. The 
hepatic portal vein was cannulated and the liver was infused with a perfusion buffer (1xHBSS 
Ca++/Mg++ free, 100 U/ml penicillin, 100 µg/ml streptomycin, 10 mM HEPES) at 8.2 ml/min. 
The portal vein and diaphragm were cut and the superior vena cava was clamped. After 10 
minutes with the first perfusion buffer, the buffer was changed to a second perfusion buffer 
(1xHBSS with Ca++/MG++, 100 U/ml penicillin, 100 µg/ml streptomycin, 10 mM HEPES, 0.025 
mg/ml collagenase, Roche Liberase TM). Colleganase digestion continued for ~7-10 minutes 
until signs of digestion were observed. The perfusion pump was stopped and the liver was 
excised. The liver was placed in 100 ml sterile beaker containing 20-30 mls of a cold third buffer 
(1xHBSS Ca++/Mg++ free, 100 U/ml penicillin, 100 µg/ml streptomycin, 10 mM HEPES, 1x10-7 
M Insulin). The liver was chopped with scissors and forceps and filtered through cell filters 
beginning with 100 µM, then 70 µM, and the 30 µM. Cells were collected into a 50 ml conical 
tube. Cells were centrifuged in a volume of 50 ml at 50 g for 5 min at 4 degrees. The media was 
aspirated and the wash step was repeated 2 more times using the cold third buffer. After the 
third wash the cells were resuspended in Williams E Media (Sigma, St. Louis, MO) and viability 
was determined using trypan blue. Hepatocytes were plated on collagen-coated plates (rat tail 
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collagen type I, Corning) in hepatocyte growth media (Williams E, 10% FBS, 4 mM L-glutamine, 
100 U penicillin/100 mg streptomycin, 2 ng/mL rat EGF, 100 nM insulin, 100 nM 
dexamethasone, 0.1% BSA, 10 mM sodium pyruvate). For fatty acid oxidation experiments 
hepatocytes were plated into a 12-well plate (2x105 cells/well). For all other experiments, 
hepatocytes were plated in 6 well plates (1x106 cells/well). For lipid exposure experiments, cells 
were treated with 250 µM Palmitate for 24 h. Palmitate was conjugated to 1% BSA in 
hepatocyte growth media. Further cell experiments are described below.  
siRNA transfection. Hepatocytes were transfected with 15 nM HSP72 siRNA 
(NM_212504; Sigma) or MISSION® siRNA Universal Negative Control #1 using Mission siRNA 
transfection reagent (Sigma) according to the manufacturer’s protocol in hepatocyte growth 
media. Hepatocytes were harvested 24-48 h after transfection, and knockdown was confirmed 
by western blot.  
Heat treatment in primary hepatocytes. Hepatocytes were heat treated (42°C) or sham 
treated (37°C) in a water bath for 30 minutes, and growth media was changed immediately 
after. Experiments continued 24 hours following heat treatment.  
Lipid droplet detection. Along with siRNA or heat treatment, cells were treated with 
Palmitate or Vehicle as described above.  Cells were then treated with 3.8 µM Bodipy 493/503 
(D3922; Thermo Fisher Scientific, Rockford, IL) for 15 minutes in serum-free William’s E media 
and then washed with 1xPBS.  Cells were then imaged live using confocal imaging.  Images 
were acquired with the Nikon A1 Confocal Live Cell Scanning Microscope (Melville, NY). 
Triglyceride content. Triglyceride content from various tissues was evaluated as done 
previously [133, 136]. Intramuscular triacylglycerol concentration was determined based on the 
methods by Frayn and Maycock [419]. The tibialis anterior, consisting of mostly glycolytic 
muscle fibers [420], was homogenized in 3 ml of 2:1 chloroform:methanol, transferred to 13x100 
mm borosilicate glass tubes, vortexed, and incubated overnight at 4˚C. The following day, 3 ml 
of 4 mmol/l MgCl2 was added to each tube, vortexed, and centrifuged at 1,000 g for 1 h at 4˚C. 
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The bottom organic layer (1.5 ml) was drawn off and placed into clean borosilicate glass tubes, 
allowed to dry overnight, reconstituted with 500 µl of ethanolic KOH, and heated at 75°C for 20 
min. Following heating, 1 ml of 0.15 mmol/l MgSO4 was added to each tube, centrifuged at 
1,000 g for 1 h at 4°C, and supernatant removed and assayed for triglyceride and free glycerol 
concentration using a commercially available colorimetric assay (F6428, Sigma). Liver was 
processed similarly except that after drying overnight, samples were reconstituted in butanol – 
Triton X-110 and assayed directly afterwards [133]. 
Liver triacylglycerol concentration was also detected from primary hepatocytes. Cells 
were harvested using lysis buffer (0.03% SDS in PBS), followed by addition of 1 ml of 2:1 
chloroform/methanol to each tube of lysate. The tubes were centrifuged for 1 h (1000 g, 4 C) 
and the organic layer was transferred to a clean Eppendorf tube. Tubes were then transferred to 
a fume hood for 48-72 h to evaporate the organic phase, and then each sample was 
reconstituted in 75 ul of butanol: Triton X-114 (3:2). Glycerol content was evaluated to measure 
lipid content and was determined by using the Glycerol Free Reagent kit (F6428; Sigma). 
Optical density was evaluated at 540 nm. 
Mitochondrial quality measurement. Hepatocytes were treated with 100 nM MitoTracker 
Green FM (M7514; Thermo Fisher) in William’s E Media, a green fluorescent mitochondrial stain 
which localizes to mitochondria regardless of mitochondrial membrane potential.  Cells were 
also stained with 600 nM tetramethylrhodamine, ethyl ester (TMRE) (T669; Thermo Fisher) in 
William’s E Media, which is a red florescent stain sequestered by active mitochondria. Cells 
were washed with warm PBS, stained with both stains for 30 min, and then washed again with 
warm PBS. Cells fixed with 3.7% PFA and imaged with confocal imaging.  Images were 
acquired with the Nikon A1 Confocal Live Cell Scanning Microscope. 
Fatty acid oxidation. Fatty acid oxidation (FAO) was determined in primary hepatocytes 
based on previous protocols [252]. Primary hepatocytes in 12-well plates were serum starved 
and then washed with warm PBS. Cells were then incubated in FAO reaction medium 
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containing DMEM-low glucose (Invitrogen), 0.5 µCi/ml [1-14C] palmitate, 100 µM palmitate 
,0.25% BSA, 1 mM carnitine, and 12.5 mM HEPES (pH ~7.4) at 37°C for 3 h in triplicate. To 
identify carnitine palmitoyltransferase-1 (CPT-1)-mediated FAO, some wells were treated with 
the CPT-1 inhibitor etomoxir (100 µM). CPT-1-mediated FAO is calculated as the difference 
between total FAO and FAO in the presence of etomoxir. After 3 h, the medium from each well 
was collected, and an aliquot of medium was put into the sealed trapping device. The 14CO2 was 
driven from the media aliquot by addition of perchloric acid and trapped in NaOH, which was 
collected and analyzed by liquid scintillation counting for determination of complete FAO to CO2. 
The acidified media was collected, refrigerated, and centrifuged (16,000 g, 4°C). An aliquot was 
analyzed by liquid scintillation counting for determination of the acid-soluble metabolites (ASMs) 
of FAO. ASMs are radiolabeled fatty acids which have not been completely oxidized to CO2, 
thus represent incomplete FAO. The cells were rinsed three times with ice-cold Krebs-Henseleit 
buffer and lysed with SDS lysis buffer. The protein concentration of the lysate was determined 
by BCA assay. 
Transmission Electron Microscopy. The tissue was fixed with 2% glutaraldehyde in 0.1M 
Cacodylate buffer. Tissue was rinsed 2Xs 10 min each with Cacodylate buffer. Tissue was post 
fixed in 1% osmium tetroxide buffered, for 1 hour. Tissue was rinsed 3Xs 10 min each with 
distilled water. Tissue was dehydrated in a graded series of ethanol as follows: 50%, 70%, 80%, 
95%, 100%,100% 10 min each. Tissue was placed into propylene oxide 2Xs 20 min each then 
transferred to a half/half mixture of propylene oxide/Embed 812 medium mixture resin (Electron 
Microscopy Sciences, Fort Washington PA) samples were left to infiltrate overnight. Tissue was 
placed into 100 Embed 812 resin for 1 h. They were then placed into BEEM capsules size 00 
and cured overnight in a 65°C oven. The individual sample blocks were sectioned using a 
Diatome diamond knife on a Leica UC-7 ultramicrotome at 80nm thick and picked up on 200 




Western blotting. Muscles and liver were processed for Western blotting by methods 
previously described [268, 297, 386]. Briefly, muscle and liver tissue were homogenized in a 
12:1 (volume-to-weight) ratio of ice-cold cell extraction buffer containing 10 mmol/l Tris·HCl (pH 
7.4); 100 mmol/l NaCl; 1 mmol/l each of EDTA, EGTA, NaF, and phenylmethylsulfonyl fluoride; 
2 mmol/l Na3VO4; 20 mmol/l Na4P2O7; 1% Triton X-100; 10% glycerol; 0.1% SDS; 0.5% 
deoxycholate; and 250 µl/5 ml protease inhibitor cocktail. Homogenates were rotated for 30 min 
at 4°C, and then centrifuged for 20 min at 3,000 rpm at 4°C and the supernatant was removed.  
Before harvesting for western blots, hepatocytes were serum starved for 6 h. Cells for western 
blotting were rinsed with PBS scraped, collected, and pelleted. The cell pellets were lysed in 
RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM 
EDTA, 1 mM PMSF, 1 mM NaF, 1mM NA3VO4, and protease inhibitors (Thermo Fisher)) and 
were centrifuged at 12,000 rpm x 12 min 4°C. The protein content of the supernatant for tissue 
homogenates and cell culture determined by Bradford assay and lysates were stored at -80°C 
until analysis.  
Samples were diluted in HES buffer and Laemmli buffer containing 100 mmol/l 
dithiothreitol (DDT) (Thermo Fisher) based on protein concentration to generate samples 
containing equal concentration of protein. Samples were heated in a boiling water bath 5 min. 
For assessment of mitochondrial complexes, samples were diluted in HES buffer, non-reducing 
lane marker buffer not containing DDT (Thermo Fisher), and were not boiled. Protein (20-80 µg) 
was separated on SDS-PAGE gels, followed by a wet transfer to a nitrocellulose membrane for 
1.5-4 h at 200-250 mA. Membranes were blocked in Tris-buffered saline (TBS), 0.1% Tween 20 
(TBST), and 5% nonfat dry milk or 5% bovine serum albumin (BSA) followed by incubation with 
the appropriate primary antibodies. Following three brief washes with TBST, blots were 
incubated with an appropriate HRP-conjugated secondary antibody in TBST 1% nonfat dry milk 
or BSA at a concentration of 1:10,000 for 1 h at room temperature. Blots were then washed 
twice with TBST and once with TBS, dried, and visualized by Enhanced chemiluminescence 
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(ECL). Bands were quantified using Image J or Image Lab densitometry. Blots from liver and 
muscle were then stripped for 15-20 min at 55°C in buffer containing 62.5 mmol/l Tris·HCl, 2% 
SDS, and 100 mmol/l 2-mercaptoethanol and re-probed for α-tubulin or β-actin as a loading 
control. Ponceau (Sigma) was used as a loading control from cell culture studies.  
Antibodies. HSP72 primary antibody (cat. no. SPA-810) and Cytochrome c (cat no. 
AAM-175) were purchased from Enzo Life Sciences (Farmingdale, NY). PGC-1α (cat. no. 
516557) was purchased from Cal-Biochem (Darmstadt, Germany). MitoProfile Total OXPHOS 
Rodent WB Antibody Cocktail (cat. no. 110413) was purchased from MitoSciences (Eugene, 
Oregon). Bradford protein quantification reagent was purchased from Bio-Rad (Hercules, CA). 
Secondary antibodies used included goat anti-mouse (cat no. 170-5047, BioRad), donkey anti-
rabbit (711-035-152, Jackson Immuno-Research, Inc., West Grove, PA), and goat anti-rabbit 
(cat no. sc-2004; Santa Cruz Biotechnology). Enhanced chemiluminescence reagents were 
purchased from Thermo Fisher.  
Statistical Analysis. Results are presented as mean ± SEM. Statistical significance was 
set at P < 0.05. Analysis was performed using Sigma Plot for Windows, version 12.0 (Systat 
Software Inc., Chicago, IL). Data were compared by an unpaired t-test, one-way ANOVA, or 
two-way ANOVA using Fisher’s post-hoc differences performed where appropriate. Where raw 
values did meet the assumptions of equal variance or normal distribution, values were 
logarithmically, square root, or reciprocal transformed. 
 
3.4 Results 
At the end of the initial 8 wk period of high-fat feeding, body weight (Sham: 498.8 ± 19.1 
g, Heat: 492.1 ± 15.7 g) and daily food intake (Sham: 19.2 ± 0.8 g/d, Heat: 19.4 ± 1.1 g/d) were 
similar prior to beginning HT or ST. During the 7 wk HT or ST period there was a strong trend 
for HT rats to gain less weight on the high-fat diet (HFD) compared to ST animals (P = 0.056, 
Figure 9A). Food intake was not significantly different following HT (Figure 9B). Energy 
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efficiency, calculated as the change in body weight divided by the kilocalories consumed during 
this period, was 19% lower in the HT rats compared to ST (P < 0.05, Figure 9C). Coinciding 
with modest changes in body weight, the weight of the eWAT (Sham: 17.1 ± 2.0 g, Heat: 14.3 ± 
1.2 g), subcutaneous white adipose tissue (SCAT) (Sham: 9.3 ± 1.5 g, Heat: 6.7 ± 1.1 g), and 
brown adipose tissue (BAT) (Sham: 729.4 ± 67.3 mg, Heat: 700.0 ± 38.7 mg) were not 
significantly different between HT and ST rats. However, adipocyte size in the eWAT was 28% 
















Figure 9. Body weight related changes following weekly heat treatment in rats fed a HFD.  
(A) Change in body weight, (B) food intake, (C) energy efficiency, and (D) cross-sectional area 
of adipocytes from eWAT in rats fed a HFD for 15 kw and receiving weekly in vivo ST (37˚C, 20 
min) or HT (41˚C, 20 min) during the last 7 wk of the HFD. (E) Representative images of 10 µm 
thick sections of eWAT stained with H&E. Bar represents 50 µm. * P < 0.05, ***P < 0.001 
denotes a significant difference between groups determined by unpaired t-test. Values are 




Heat treatment, glucose tolerance, and insulin sensitivity 
Whole-body insulin resistance has been consistently shown in rats after just 3-6 wk of 
high-fat feeding [418, 421-423]. Fasting blood glucose concentration was not significantly 
different between ST and HT rats (Figure 10A), and fasting insulin concentration was only 
modestly reduced following HT (P = 0.07, Figure 10B). Following an intraperitoneal injection of 
glucose one wk prior to the final ST/HT, and 48 h after the last ST/HT, HT rats had significantly 
lower blood glucose concentrations compared to ST (main effect of treatment P < 0.05, Figure 
10C), as well as 20% lower glucose area under the curve (AUC) values (P < 0.05, Figure 10D).  
Insulin concentration was significantly lower 30 min following glucose injection in HT rats 
compared to ST, but was not significantly different 60 min, 90 min, or 120 min following injection 
(Figure 10E). Insulin AUC values were not significantly different between HT and ST rats 
(Figure 10F). Serum triglycerides were not significantly different between ST (120.7 ± 11.3 
mg/dl) and HT rats (114.3 ± 17.1 mg/dl), and serum NEFA concentration were not significantly 
different between ST (0.469 ± 0.04 mmol/l) and HT animals (0.421 ± 0.04 mmol/l). 
We also evaluated skeletal muscle insulin sensitivity in both the soleus and EDL muscle 
of ST and HT rodents. The EDL is a composed of primarily glycolytic type II muscle fibers while 
the soleus is composed primarily of oxidative type I muscle fibers [420]. In the EDL of HT rats, 
we observed significantly greater insulin-stimulated glucose uptake compared to ST rats (P < 
0.05) (Figure 10G). In the soleus, we did not observe significant differences in insulin-






Figure 10. Heat treatment improves glucose tolerance and insulin-stimulated glucose 
uptake in rats fed a HFD.  
(A) Fasting blood glucose and (B) serum insulin concentration in rats fed a HFD for 15 wk and 
receiving weekly in vivo ST (37˚C, 20 min) or HT (41˚C, 20 min) during the last 7 wk of the HFD. 
Blood glucose (C) and insulin concentrations (E) in response to an intraperitoneal (i.p.) glucose 
injection, and AUC of glucose (D) and AUC  (F) of insulin following i.p. glucose injection. Rats 
were fasted overnight one week prior to sacrifice and were injected with a glucose load of 2 g/kg 
body weight intraperitoneally. Blood glucose was measured prior to, and 30, 60, 90, and 120 
min following injection using a glucometer. Differences between groups were determined by 
unpaired t-tests at each GTT time point and also when comparing AUC and fasting glucose and 
insulin levels. * P < 0.05 (G) Insulin-stimulated glucose uptake in the EDL muscle in ST and HT 
rats. Insulin-stimulated glucose uptake was determined by incubating muscles in the presence 
or absence of 1 mU/ml insulin for exactly 20 min. † P < 0.05 denotes insulin-stimulated glucose 
uptake is significantly greater than basal determined by one-way ANOVA with Fisher’s post hoc 
















Liver and skeletal muscle responses to heat treatment 
Induction of HSP72 by HT was then determined in skeletal muscle and liver. HSP72 
levels were 315% greater in the EDL of HT rats compared to ST (P < 0.001, Figure 11A), but 
HSP72 levels were not significantly different between HT and ST rats in the soleus (Figure 
11B). Hepatic HSP72 protein expression was 54% greater following HT compared to ST (P < 
0.01, Figure 11D). In addition to HSP72 induction, we also evaluated triglyceride storage in 
muscle and liver. We observed that in the tibialis anterior, a primarily glycolytic muscle [420], 
triglyceride content was 20% lower in HT rats compared to ST (P < 0.05, Figure 11C). Hepatic 
triglyceride content was reduced to an even greater extent, by 50%, in HT, HFD-fed rats 
























Figure 11. Heat treatment induces HSP72 and decreases triglyceride content in muscle 
and liver.  
ST and HT rats were fed a HFD for 15 wk and received weekly in vivo ST (37˚C, 20 min) or HT 
(41˚C, 20 min) during the last 7 wk of the HFD. ( A,B) HSP72 protein expression in the EDL and 
soleus, (C) triglyceride content in tibialis anterior, (D) hepatic HSP72 expression, (E) and 
hepatic triglyceride content were compared between ST and HT rats. * P < 0.05, ** P < 0.01 
denotes significantly different between treatment groups determined by unpaired t-test. Values 








Loss of HSP72 in primary hepatocytes disrupts mitochondrial integrity 
  Exposure to siRNA for HSP72 in primary hepatocytes resulted in a 58% knockdown of 
protein expression following HT (P < 0.01, Figure 12A). Control and HSP72 siRNA treated 
hepatocytes were examined by transmission electron microscopy to evaluate differences in 
mitochondrial morphology. Mitochondria treated with siHSP72 were larger and swollen 
compared to control siRNA treated cells (Figure 12B). Hepatocytes treated with control siRNA 
or siHSP72 were also stained with MitoTracker green, a dye taken up by both functional and 
nonfunctional mitochondria (Figure 12C, middle images in green labeled B and E) and 
tetramethylrhodamine ethyl ester, (TMRE) a poteniometric dye taken up only by functional 
mitochondria (Figure 12C images in red labeled A and D). We observed reduced TMRE 
staining in siHSP72 treated cells without observing changes in MitoTracker green staining 
(Figure 12C, images C and F). Lower TMRE staining demonstrates a decrease in functional 











Figure 12. HSP72 knockdown in primary hepatocytes disrupts mitochondrial integrity.  
(A) Primary hepatocytes from C57/Bl6 mice were transfected with HSP72 siRNA or control 
siRNA and heat-treated 24 hours later. A 58% knockdown of HSP72 protein expression was 
observed 24 hours following HT. **P < 0.01, denotes significantly different between treatment 
groups determined by unpaired t-test. Values are mean ± SEM. N=3. (B) Primary hepatocytes in 
the presence or absence of HSP72 were imaged through Transmission Electron Microscopy. 
Representative images are shown. C) Primary hepatocytes treated with control siRNA or 
siHSP72 were stained with MitoTracker Green (middle images in green) to stain all 
mitochondria, and TMRE (left images in red) which stains only mitochondria with intact 
membrane potentials. The right images are merged MitoTracker/TMRE images. Representative 
images are shown. 
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Mitochondrial protein expression was then evaluated to determine if reductions to 
mitochondrial integrity were paralleled by reductions in mitochondrial protein expression. There 
was no significant difference in protein expression of PGC-1α or Electron Transport Chain 
(ETC) Complexes between control siRNA treated and HSP72 siRNA treated hepatocytes 
(Figure 13, A, C). However, cytochrome c protein expression increased by 20% with a loss of 
HSP72 (P < 0.05, Figure 13B). These data suggest that an acute loss of HSP72 does not 






















Figure 13. The effect of HSP72 reduction on mitochondrial protein expression.  
Primary hepatocytes from C57/Bl6 mice were transfected with HSP72 siRNA or control siRNA. 
Protein expression levels of (A) PGC-1α and (B) Cytochrome c. * P < 0.05, denotes significantly 
different between treatment groups determined by unpaired t-test. Values are mean ± SEM. 







A loss of HSP72 in primary hepatocytes reduces fatty acid oxidation  
To determine if mitochondrial function was altered by an acute loss in HSP72 
expression, fatty acid oxidation (FAO) of 14C palmitate was assessed in control siRNA and 
siHSP72-treated primary hepatocytes. Incomplete FAO (Figure 14A), complete FAO through 
the TCA cycle to CO2 (Figure 14B), and total FAO (incomplete + complete FAO to CO2) (Figure 
14C) were evaluated. A separate set of hepatocytes were also treated with etomoxir, an 
inhibitor of CPT-1, which allows for determination of differences between mitochondrial FAO 
and non-mitochondrial FAO mediated by other organelles. 
 Loss of HSP72 resulted in a 20% reduction of incomplete FAO (P<0.001, Figure 14A) 
and a 19% reduction in total FAO (P < 0.01, Figure 14C). Complete FAO to CO2 was not 
different between groups (Figure 14B). Mitochondrial incomplete FAO (19%, P<0.01) and non-
mitochondrial incomplete FAO (23%, P < 0.01) were significantly decreased with a loss of 
HSP72. Reductions in mitochondrial total FAO (16% P < 0.05) and non-mitochondrial total FAO 
(22%, P < 0.01) were also observed in siHSP72 treated hepatocytes. Additionally, siHSP72 
treatment resulted in a 26% decrease in non-mitochondrial complete FAO (P < 0.05). No 
significant difference in mitochondrial complete FAO was observed with a reduction in HSP72. 
Collectively, these data suggest that a loss of HSP72 decreases total FAO in primary 





Figure 14. Knockdown of HSP72 alters primary hepatocyte fatty acid oxidation.  
14C-radiolabeled FAO of palmitate (100µM) in primary hepatocytes was evaluated in the 
presence and absence of the CPT-1 inhibitor etomoxir (100 µM) allowing for the evaluation of 
mitochondrial and non-mitochondrial mediated FAO separately and together (combined FAO). 
Incomplete FAO, complete FAO to CO2, and total FAO were determined. A) Incomplete, 
combined FAO (black bars), non-mitochondrial incomplete FAO (white bars) and mitochondrial 
incomplete FAO (gray bars) in control siRNA and siHSP72 treated hepatocytes. B) Complete, 
combined FAO to CO2 (black bars), non-mitochondrial complete FAO to CO2 (white bars), and 
mitochondrial complete FAO (gray bars). C) Total FAO (determined by adding incomplete and 
complete FAO to CO2) (black bars), non-mitochondrial total FAO, and mitochondrial total FAO 
(gray bars). * P < 0.05, ** P < 0.01, *** P < 0.001 denotes significantly different between 
treatment groups determined by unpaired t-test between control siRNA and siHSP72 groups. 







HSP72 expression in primary hepatocytes modulates lipid storage 
The impact of altering HSP72 protein expression on lipid accumulation was evaluated in 
primary hepatocytes. Palmitate treatment increased triglyceride (TAG) 161% in control siRNA 
treated hepatocytes (P < 0.001, Figure 15A and 15B). When compared to control siRNA 
treated hepatocytes, siHSP72-treated hepatocytes had 77% greater lipid accumulation following 
24 h of palmitate treatment (250 µM) (P < 0.001, Figure 15A and 15B, black bars). In addition, 
non-palmitate, siHSP72 treated hepatocytes demonstrated a 177% increase in lipid 
accumulation compared to control (P<0.001, Figure 15B, white bars).  
A separate set of hepatocytes were exposed to ST (37°C) or HT (42°C) for 30 minutes in 
order to increase HSP72 protein expression. HT was performed after 24 h of palmitate 
treatment. Palmitate treatment increased hepatic TAG by 95% in ST hepatocytes (P < 0.001, 
Figure 15C and 15D). However, HT blunted lipid accumulation in primary hepatocytes. TAG 
accumulation was 29% lower in HT hepatocytes compared to ST hepatocytes following 24 h 






Figure 15. HSP72 modulates lipid storage in primary hepatocytes.  
A) Primary hepatocytes from C57/Bl6 mice were first treated with control siRNA or siRNA for 
HSP72 for 24 h and then with 250 µM Palmitate or Vehicle for 24 h. Cells were then stained with 
Bodipy for 20 min prior to imaging at 40X to assess triacylglycerol content. B) Liver 
triacylglycerol (TAG) content was also determined biochemically through a colorimetric assay. 
C) In separate experiments, cells were treated with Palmitate (250µM) or Vehicle for 24 h, and 
then exposed to ST (37ºC) or HT (42ºC) for 30 min. Following these treatments, cells were 
stained with Bodipy and imaged. D) Biochemical liver TAG was also determined. ** P < 0.01 
and *** P < 0.001 denotes significant differences between siRNA treatment groups. # P< 0.01 
and † P< 0.001 denotes significant differences between vehicle and palmitate treatments. 
Significant differences were determined by two-way ANOVA with Fisher’s post hoc analysis 






NAFLD is the liver component of metabolic disease and is highly prevalent [424]. 
Currently, mechanisms underlying this condition are not well understood. HSPs are known to 
play important roles in skeletal muscle and systemic metabolism, but their potential roles in liver 
metabolism are unclear. In this study, we investigated the effect of in vivo HT intervention on 
whole-body and liver-specific metabolic outcomes. We also investigated the effect of HSP72 
modulation on mitochondrial integrity and lipid handling in primary hepatocytes. Through a 
combination of these in vivo and in vitro experiments, we demonstrated that in vivo HT induces 
hepatic HSP72 expression and reduces lipid storage in the liver. We also found that HSP72 is 
important in maintaining mitochondrial integrity and FAO, as well as preventing lipid storage in 


















Figure 16. The role of hepatic HSP72 on lipid handling and whole-body metabolic 
homoeostasis.  
HSP72 was found by Di Naso et al. to be reduced with the progression of NAFLD and NASH. 
Based on the results of this study, we propose that heat treatment intervention and other 
treatments that induce hepatic HSP72 can improve lipid handling in the liver through increasing 
fatty acid oxidation and reducing lipid storage. This can lead to improved whole-body insulin 







In addition to identifying liver-specific outcomes in this study, these are the first findings 
to indicate the ability of HT to reverse the damaging metabolic effects of a prior HFD. Previously 
we showed that 12 wk of weekly in vivo HT prevented HFD induced whole-body and skeletal 
muscle insulin resistance [268]. In the present study, we expand upon these findings by 
showing that after 8 wk of high-fat feeding, weekly in vivo HT improved whole-body glucose 
tolerance and increased insulin sensitivity in glycolytic skeletal muscle. In addition, weight gain 
was blunted by weekly HT and energy efficiency was reduced, indicating that energy utilization 
had been altered. Adipocyte size was reduced by weekly HT in the eWAT, although fat pad 
mass was not significantly reduced. Our results agree with prior studies showing HT, transgenic 
overexpression, or GGA administration to induce HSP72 levels reduces WAT mass and 
adipocyte size [266, 268, 295]. Adipocytes are known to play a large role in whole-body glucose 
homeostasis [425], and smaller adipocytes are generally more insulin sensitive [426]. Like 
reduced triglyceride storage in the liver, we also observed reduced triglyceride storage in 
skeletal muscle with HT. Increased lipid storage in the skeletal muscle has been shown to 
generate secondary messengers (i.e., DAGs and ceramides) that inhibit insulin signaling [427, 
428]. In the present study, we observed lower triglyceride content in glycolytic skeletal muscle of 
HT rats fed a HFD in association with increased insulin-stimulated glucose uptake.  
As excess lipid accumulation in the liver is a hallmark of NAFLD, reductions in 
triglyceride storage observed here represent a potential treatment modality that has not been 
widely explored. Past work by our laboratory and others has identified increased hepatic HSP72 
protein expression with heat and exercise [268, 365, 366, 429], however, these studies did not 
investigate the ability of HSP72 to affect liver steatosis. Adachi et al. reported that induction of 
HSP72 by administration of the compound GGA ameliorated hepatic insulin resistance and 
reduced JNK phosphorylation [295], but hepatic triglyceride content was not measured. Reports 
using mild electrical stimulus coupled with heat stress have shown reduced triglyceride storage, 
reduced inflammation, and increased insulin responsiveness in the liver of high-fat fed mice and 
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db/db mice [430, 431]. In these reports, HSP levels were not measured. Work from Di Naso et 
al. also supports that HSP72 activation may be important in the prevention of NAFLD, since 
they found that decreased HSFP72 levels correlated with NAFLD progression in humans [264]. 
Maybe one of the most promising studies linking HSP72 to liver metabolism is one by Zeng et 
al. which investigated pharmacological activation of HSP72 by the small molecule drug matrine. 
In mice, matrine increased hepatic HSP72 protein content and also reduced liver triglyceride 
storage and glucose intolerance [301]. In the current study, we observed that both HSP72 and 
HSP25 protein expression levels are induced in the liver by weekly HT in rats fed a HFD. 
Weekly HT also reduced hepatic triglyceride content. Our results expand on past research 
through identifying HT as a treatment modality to induce HSP72 and reduce triglyceride storage 
in the liver.  
Based on our results from weekly in vivo HT, we then aimed to identify if HSP72 has a 
more direct role in the protection against lipid accumulation in hepatocytes. We found with a 
loss of HSP72, primary hepatocytes demonstrated a reduction in mitochondrial integrity as 
shown by reduced mitochondrial membrane potential and changes in morphology. We also 
found that mitochondrial total FAO of palmitate was reduced with a decrease in HSP72 
expression. The most interesting results of this study are the robust effects of HSP72 
modulation on lipid storage in primary hepatocytes. We found that with an acute loss of HSP72, 
lipid accumulation was increased following palmitate exposure, while HT effectively prevented 
lipid accumulation. The consistency in results from our in vivo HT experiments and in vitro 
studies are very promising to identify HSP72 induction as a strategy to prevent NAFLD. 
 Identifying the effects of HSP72 loss on mitochondrial integrity and FAO is important 
due to the strong mitochondrial component in the development of NAFLD [226, 227]. Similar to 
our observations with a loss of HSP72 in primary hepatocytes, mitochondrial morphology is 
altered and a loss of cristae and swelling of the mitochondria is observed with diabetes and 
NAFLD [202, 205, 253, 254]. Past research in rodent models also provides strong evidence that 
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FAO contributes to the progression of NAFLD.  FAO in the liver is an essential part of hepatic 
lipid metabolism, and dysregulation of this process results in hepatic steatosis. Studies have 
shown that a reduction or genetic defect of hepatic β-oxidation enzymes leads to increased 
steatosis in the liver of rodents [198, 229], and an increase in β-oxidation enzymes reduces 
hepatic steatosis [199]. Additionally, Rector et al. also showed that in a hyperphagic rodent 
model a reduction of FAO occurs before the progression to hepatic steatosis or insulin 
resistance [230]. However, there isn’t evidence that decreased FAO contributes to the 
development of NAFLD in humans.  Actually, some studies have found increased FAO or 
mitochondrial oxidation gene expression in patients with NAFLD and NASH [194, 200, 201, 205, 
432], although hepatic FAO in humans is difficult to accurately measure and often has small 
sample sizes [433]. Studies have found other mitochondrial deficits such as impaired ATP 
production and increased ROS with NAFLD and NASH [202-205]. It’s possible that HSP72 
regulation of FAO contributes to lipid storage, however, future research must identify the 
significance of this finding in the context of NAFLD or NASH development in humans. 
Reduced hepatic mitochondrial FAO that we observed with a loss of HSP72 is consistent 
with past work investigating HSP72 and skeletal muscle mitochondrial function.  Our laboratory 
and others have shown that HT improves skeletal muscle mitochondrial function by improving 
FAO [268], increasing mitochondrial enzyme activity [268, 314, 315], and increasing 
mitochondrial biogenesis [316]. Modulation of HSP72 levels through overexpression or knockout 
also regulates skeletal muscle mitochondrial function. Whole body and skeletal muscle HSP72 
overexpression increases mitochondrial enzyme activity in rodents [266, 269]. Skeletal muscle 
specific overexpression of HSP72 increases skeletal muscle FAO [269] and reduces skeletal 
muscle lipid storage. This was consistent with a global knockout of HSP72 which demonstrated 
reduced skeletal muscle FAO, β-oxidation enzyme activity, and increased lipid storage [317]. 
Similar to our findings in primary hepatocytes, mitochondria were enlarged and dysmorphic in 
skeletal muscle of HSP72 knockout animals. Drew et al. also found that that the mitochondrial 
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degradation pathway, mitophagy, was impaired and contributed to the accumulation of 
damaged mitochondria in skeletal muscle of HSP72 knockout animals [317]. It is probable that 
impaired mitophagy occurs with a loss of HSP72 in the liver, and future studies will need to 
investigate this interaction. 
Fatty acids are mainly oxidized in the mitochondria, through the subsequent reactions of 
β-oxidation. Acetyl-CoA is produced which then may enter the TCA cycle and be completely 
oxidized to CO2, which is called complete FAO [173]. Incomplete oxidation of fatty acids can 
also occur and form acid-soluble metabolites such as ketone bodies, acyl-CoAs, and 
acylcarnitines. In this study, we observed reduced total mitochondrial FAO with a loss of HSP72 
in primary hepatocytes which was driven by reductions in incomplete hepatic FAO. About two-
thirds of the fat that comes to the liver is converted into ketones [215], therefore the majority 
of FAO is directed to ketogenesis from incomplete FAO [211]. Cotter et al. showed that 
ketogenesis can be a mechanism of lipid disposal, even in non-fasted conditions, and 
dysfunction in this pathway promotes the development of NAFLD into NASH [209]. With the 
reductions we observed in incomplete FAO with a loss of HSP72, further research is needed in 
order to identify if HSP72 could be involved in regulation of ketogenic pathways and if that is 
connected to steatosis. Another aspect of FAO we evaluated was non-mitochondrial FAO. FAO 
occurs in the mitochondria and also partially in peroxisomes and microsomes [171, 194, 195]. 
With a loss of HSP72, we observed reduced complete and incomplete non-mitochondrial FAO, 
which implies a decrease in FAO in other organelles. It’s possible that HSP72 can regulate both 
mitochondrial and non-mitochondrial FAO processes, and future research should address this 
possible role of HSP72. 
 In this study we also evaluated PGC-1α, cytochrome c, and mitochondrial complexes 
and found no difference in protein expression of PGC-1α and complex proteins with a loss of 
HSP72 in primary hepatocytes, and a slight increase in cytochrome c protein content. The 
increase in cytochrome c may be a reflection of compensation by the mitochondria. Past work in 
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skeletal muscle of a whole-body HSP72 knockout animals did not evaluate PGC-1α, but they 
found no difference in cytochrome c expression or protein levels of the electron transport chain 
proteins in skeletal muscle [317]. They also found no difference in citrate synthase activity or 
mtDNA between WT and knockout animals in skeletal muscle, which are both markers of 
mitochondrial content. However, Henstridge et al. found with whole-body overexpression of 
HSP72, mitochondrial number was increased by 50% in skeletal muscle, without any observed 
changes in in PGC-1α expression. Although in this current study we did not evaluate 
mitochondrial number, based on similar or slight increase in mitochondrial protein content 
between control siRNA and siHSP72, it is likely that mitochondrial content is not affected by a 
loss of HSP72 in primary hepatocytes. This would be consistent with observations from skeletal 
muscle of whole-body HSP72 knockout animals [317]. It is also possible that other proteins or 
post-translational modifications not evaluated in this study, such as PGC-1α acetylation, could 
be affected by a loss of HSP72. These outcomes will be important to evaluate in future studies.  
It is possible that HSP72 is not only important in steatosis, but also in the advancement 
of NAFLD. In about 20% of individuals, NAFLD eventually develops into a more severe liver 
disease called non-alcoholic steatohepatitis (NASH). NASH includes inflammation and cellular 
damage that can lead to fibrosis and cirrhosis [424]. Molecular metabolic defects occur in 
stages as NAFLD and NASH progress, and these changes continue to be investigated. For 
example, Sanyal et al. found the presence of various mitochondrial defects and insulin 
resistance with both NAFLD and NASH patients, but only observed mitochondrial structural 
defects in NASH patients [205]. Studies have also found that ketogenesis is increased in early 
hepatic steatosis [207-212], but eventually is reduced with advancement into NASH [209, 210, 
212]. Additionally, Di Naso et al. found that decreased HSP72 protein content and HSF1 
content, the main transcription factor for HSP72, correlated with the advancement of NAFLD 
and NASH. It is possible that a loss of HSP72 induction contributes to the transition of NAFLD 
into NASH. Hepatic HSP72 protein content could be a potential marker of NAFLD stage, 
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although this would be difficult to measure in vivo. Heat shock proteins can also be released 
extracellularly into circulation [338, 361-364, 434]. As suggested by Di Naso et al. and others, 
future work needs to identify if extracellular HSP72 in circulation could serve as a marker of 
hepatic metabolic disease stage [264, 285, 435, 436].  
In this study, we identified that HSP72 is important in lipid handling in hepatocytes 
specifically by modifying FAO and lipid storage. One limitation of this study is the fact that we 
did not investigate more aspects of lipid handling such as lipid secretion as VLDL, which is an 
important mechanism for the liver to export lipid out of hepatocytes [190]. Our findings strongly 
support that HSP72 has a direct role in hepatocytes. However, HSP72 protein in Kupffer cells 
could also be important in the development of NAFLD and NASH. Di Naso et al. suggested that 
impaired HSP72 in Kupffer cells could increase liver inflammation as liver disease progresses 
[264]. This is important since pro-inflammatory activity of Kupffer cells seems to be a part of 
NAFLD advancement into NASH, fibrosis and cirrhosis [437-439]. Interestingly, heat-induced 
upregulation of HSP72 in Kupffer cells coincides with suppression of TNFα [302, 303]. Although 
outside the scope of this work, it is important to recognize the dual role HSP72 could have in 
hepatocytes and Kupffer cells to prevent NAFLD development. Our work utilized in vivo and in 
vitro HT and siRNA treatment in primary hepatocytes to address our research questions. To 
further identify the impact of hepatic HSP72 mechanisms in whole-body metabolic homeostasis, 
the development of a liver-specific HSP72 knockout model will be necessary in future 
investigation of these mechanisms.  
 
Conclusion 
In this study, we identified that HT improves glucose tolerance and skeletal muscle 
insulin action in HFD-fed rodents. Weekly HT also specifically improves the metabolic profile of 
the liver by inducing HSP72 and reducing lipid storage. To our knowledge, this is the first study 
to directly modulate hepatic HSP72 levels and identify the importance of HSP72 in FAO and 
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prevention of steatosis. Thus, treatments that induce the expression of HSP72 should be 

































































Heat shock proteins (HSPs) are molecular chaperones that aid in the recovery from 
stress and guard cells from future insults. HSP72, in particular, plays an important role in 
maintaining skeletal muscle insulin sensitivity and glucose homeostasis and is induced in 
skeletal muscle with heat or exercise. Less is known about HSP72 induction with exercise in the 
liver. The liver also goes through numerous metabolic adaptations following exercise, including 
possible activation of the degradation pathways autophagy and mitophagy. The purpose of this 
study was to examine the ability of various chronic and acute exercise modalities to induce 
HSP72 in the liver as well as autophagy and mitophagy pathways. Male Sprague Dawley rats 
were divided into sedentary (SED), voluntary wheel running (VWR), treadmill endurance (TM-
END) or treadmill interval sprint training (TM-IST) groups for four weeks. We found that with 
endurance treadmill training, HSP72 protein content was robustly increased in the liver.  Interval 
sprint training also increased HSP72 in the liver, while there was not a significant increase in 
HSP72 with voluntary wheel running. In response to an acute bout of exercise, increased 
HSP72 and reduced inhibitory phosphorylation of transcription factor HSF-1 were observed. 
Increased hepatic HSP72 in response to chronic and acute exercise were paralleled by 
increased autophagy (LC3-II). An increase in phosphorylation of a mitophagy protein, Parkin, 
was also observed with acute exercise. Our findings demonstrate that HSP72 expression in the 
liver is increased with both chronic and acute exercise in a time and intensity dependent 
manner. Additionally, mitophagy and autophagy protein changes could be a part of HSP72 
action with exercise.  Among the many benefits of exercise, increased hepatic HSP72 
expression with exercise could play an important role in improving hepatic metabolic function.  







Heat shock proteins (HSPs) are molecular chaperones that aid in the recovery from 
stress and guard cells from future insults [263, 415]. HSP72 is the highly inducible heat shock 
protein that can be activated in skeletal muscle with stressors such as heat and exercise [263, 
366, 440-442]. Additionally, Kurucz et al found that HSP72 is decreased in skeletal muscle of 
insulin resistant and type 2 diabetic patients [284]. Recent work by Di Naso et al. found that 
HSP72 could also be important in liver metabolism, due to decreased expression of HSP72 with 
non-alcoholic fatty liver disease progression [264].  
Our lab and others have demonstrated that increased HSP72, for example through heat 
treatment, transgenic overexpression, and pharmacological treatment, improves glucose 
tolerance, skeletal muscle insulin resistance, and mitochondrial function [266-269, 295, 297, 
416]. Mice lacking skeletal muscle HSP72 have enlarged, dysmorphic mitochondria with 
reduced muscle respiratory capacity and lipid accumulation in the skeletal muscle [317].  These 
mice also demonstrate a reduced ability to degrade mitochondria through mitophagy. This is 
important since degradation pathways such as mitophagy and autophagy are important in the 
maintenance of lipid homeostasis and mitochondrial function [257, 259, 260]. This evidence 
suggests that HSP72 could be a possible target for therapies to improve insulin sensitivity and 
hepatic mitochondrial function. Although much has been revealed in the importance of heat 
shock protein activation to improve metabolic function in skeletal muscle, there is a lack of 
knowledge in the role of heat shock proteins in the liver following exercise. Some studies have 
found increased HSP induction in the liver with exercise or heat treatment [268, 365, 366, 429], 
although the role of HSPs in the liver has not been investigated.  
The liver is essential for whole-body metabolic function metabolism and exercise 
tolerance through maintaining whole-body glucose homeostasis. The liver goes through its own 
exercise-induced set of acute and chronic adaptations such as improved fat handling [220]. This 
adaptation seems to be due to increased markers of mitochondrial function and content which 
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improve lipid metabolism [132, 133, 443-445]. Recently, a publication by Fletcher et al. 
compared the effect of various exercise modalities on hepatic mitochondrial metabolism [135]. 
In this study, mice performed voluntary wheel running, endurance treadmill running, or interval 
sprint training. Regardless of the training modality, exercise significantly improved hepatic 
mitochondrial respiration and also improved other markers of mitochondrial metabolism which 
were not always dependent on increased mitochondrial content [135]. These adaptations in the 
liver are important in the maintenance of hepatic metabolic dysfunction, although the role of 
HSPs in this process are not clear.  
The purpose of this investigation is to continue the work by Fletcher et al and evaluate 
hepatic HSP72 induction across these multiple exercise modalities and with chronic and acute 
exercise. Additionally, we also aim to identify changes in autophagy/mitophagy protein 
expression with various exercise modalities. Past studies have shown that degradation 
pathways such as autophagy increase with exercise [404, 446-450]. We hypothesize that 
HSP72 will be increased with various exercise modalities, and that we will also observe 
increased expression of autophagy and mitophagy proteins. HSP72 may be essential in the liver 
to increase mitochondrial function and activate degradation pathways to dispose of damaged 
organelles such as mitochondria. 
 
4.3 Methods 
Experimental Animals – Chronic Exercise.. Twelve-week old Sprague Dawley male rats 
(n=46) were split into into sedentary (SED), voluntary wheel running (VWR), treadmill 
endurance training (TM-END), or treadmill interval sprint training (TM-IST) groups (n=8-10 per 
group). The exercise intervention lasted 4 weeks. Rodents were individually housed in 
temperature controlled rooms (21°C) with 12:12 light:dark cycles. Rats were allowed ab libitum 
access to food and water as well as a standard rodent chow (Formulab 5008; Purina Mills, 
Brentwood, MO). Animals were sacrificed following 24 hours after the last bout of exercise or 24 
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hours after locking the wheels of the VWR animals. Animals from all groups were also fasted 
starting 18 hours prior to exercise. At the end of the experiment (16 weeks old) the rats were 
anesthetized with pentobarbital sodium (100 mg/kg) and the heart was removed. The animal 
protocol was approved by the Institutional Animal Care and Use Committee at the University of 
Missouri-Columbia [135].  
Experimental Animals – Acute Exercise. The animal protocol was approved by the 
Institutional Animal Care and Use Committee at the University of Kansas Medical Center. 
Twelve male Sprague Dawley rats were purchased from Charles River Laboratories and were 
randomly assigned (n=2-5 per group) into fed sedentary (SED), fed acute treadmill exercise 
(EX-FED), or fasted acute treadmill exercise (EX-FASTED). All animals were housed in a 
temperature controlled facility (22 ± 2˚C) with 12:12 hr light:dark cycles. Animals were allowed 
ad libitum access to water and a standard chow diet (9604; Harlan Teklad, Madison WI, USA). 
Two hours post-exercise, rats were anesthetized with pentobarbital sodium (100 mg/kg) and 
then exsanguinated by removal of the heart.  
Chronic exercise protocol. Rats were randomly assigned into four groups of SED, VWR, 
TM-END, or TM-IST rats. VWR animals had running wheels available in their cages. Wheel 
revolutions of the wheels were counted throughout the intervention period using VitalView 
software (VitalView, Version 4.2, 2007; Mini Mitter Company, Inc., Bend, OR). Animals in the 
treadmill groups (TM-END or TM-IST) went through an acclimation period for five days 15 
m/min, 5-10 min/day). During the first 1.5 weeks of treadmill exercise, the animals gradually 
worked up to a higher speed. The TM-END group of rats began at 20 m/min for 10 minutes 
(12% gradient) and progressively increased to 30m/min for 60 minutes (12% gradient). They 
maintained this speed for 5 days/week during the entire four weeks. Similarly, the TM-IST group 
began with 6 short, intense bouts of exercise at 35 m/min for 1 minute (12 % gradient, 4.5 
minutes rest in between exercise bouts). They slowly increased to six 50m/min sprints for 2.5 
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minutes (12% gradient,  4.5 minutes rest in between exercise bouts). Treadmill groups 
performed exercise in the morning.  
Acute exercise protocol. Rodents were separated into three groups of SED, EX-FED, or 
EX-FASTED (~515 g). Animals were acclimatized for four days on the treadmilll prior to 
exhaustive exercise bout. Acclimatization was for ~5 min at 0 m/min on day one, 15 m/min on 
day two, 15 m/min one day three, and 20 m/min on day four.  EX-FASTED animals were fasted 
for 12 hours prior to exhaustive exercise bout. The exhaustive exercise bout began for 5 min at 
20 m/min and increased to 25 m/min until exhaustion (~45-50 min). The exercise was stopped 
when rodents stayed on the shock grid three times for 5 seconds. SED animals were placed on 
locked treadmill throughout the same amount of time as exercised animals during 
acclimatization and during the exhaustive exercise bout.  
Western blot. Liver was processed for Western blotting by methods previously described 
[268, 297, 386]. Briefly, liver was homogenized in a 12:1 (volume-to-weight) ratio of ice-cold cell 
extraction buffer (Biosource, Invitrogen) containing 10 mM Tris·HCl (pH 7.4); 100 mM NaCl; 1 
mM each of EDTA, EGTA, NaF, and phenylmethylsulfonyl fluoride; 2 mM Na3VO4; 20 mM 
Na4P2O7; 1% Triton X-100; 10% glycerol; 0.1% SDS; 0.5% deoxycholate; and 250 µl/5 ml 
protease inhibitor cocktail. Homogenates were rotated for 30 min at 4˚C, and then centrifuged 
for 20 min at 3,000 rpm at 4˚C. The supernatant was removed and protein concentration 
determined by Bradford assay. Samples were diluted in HES buffer and Laemmli buffer 
containing 100 mM dithiothreitol (DDT) (Thermo Scientific, Rockford, IL, USA) based on protein 
concentration to generate samples containing equal concentration of protein. Samples were 
heated in a boiling water bath for 5 min.  
Protein (40-80 µg) was separated on SDS-PAGE gels, followed by a wet transfer to a 
nitrocellulose membrane for 90 min at 200 mA. Membranes were blocked in Tris-buffered saline 
(TBS), 0.1% Tween 20 (TBST), and 5% nonfat dry milk or 5% bovine serum albumin (BSA) 
followed by incubation with the appropriate primary antibodies. Following three washes with 
105 
 
TBST, blots were incubated with an appropriate horseradish peroxidase (HRP)-conjugated 
secondary antibody in TBST 1% nonfat dry milk or BSA at a concentration of 1:10,000 for 1 hr 
at room temperature. Blots were then washed twice with TBST and once with TBS, dried, and 
visualized by enhanced chemiluminescence (ECL). Bands were quantified using Image J or 
Image Lab (Bio-Rad) densitometry. Blots were then stripped for 15-20 min at 55˚C in buffer 
containing 62.5 mM Tris·HCl, 2% SDS, and 100 mM 2-mercaptoethanol and re-probed for β-
actin as a loading control.  
Primary antibodies used included HSP72 (cat no. SPA-810, Enzo Life Sciences, 
Farmingdale, NY), HSP25 (cat no. SPA-801, Enzo Life Sciences), HSP60 (cat no. SPA-807, 
Enzo Life Sciences), LC3B (cat no. 2775, Cell Signaling Technology, Inc., Danvers, MA), p62 
(cat no. 5114, Cell Signaling), pParkin (phospho s65) (cat no. ab154995, Abcam, Cambridge, 
MA), Parkin (cat no. sc-32282, Santa Cruz Biotechnology, Dallas, Texas), HSF-1 (cat no. 
NB300-730, Novus Biologicals, Littleton, CO), and pHSF-1 serine 303 (cat no. ab47369, 
Abcam)  and β-actin HRP-conjugated (cat no. ab20272, Abcam). Secondary antibodies used 
included goat anti-mouse (cat no. 170-5047, BioRad, Hercules, CA) donkey anti-rabbit (cat no. 
711-035-15, Jackson, Immuno-Research, Inc., West Grove, PA), and goat anti-rabbit (cat no. 
sc-2004; Santa Cruz Biotechnology). 
 
4.4 Results 
Rodent characteristics and mitochondrial function 
 As describe in the published work by Fletcher et al. [135], following four weeks of 
exercise, TM-END and TM-IST groups had reduced body weight compared to the SED and 
VWR groups.  All exercise groups had significantly reduced body fat compared to the SED 
group. Additionally, both SED and VWR animals had increased feeding efficiency compared to 
the other exercise groups. Fletcher et al. also measured mitochondrial function through 
evaluating mitochondrial respiration. All exercised animals regardless of exercise modality had 
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increased oxidative phosphorylation as demonstrated by increased flux through complex I and 
also increased maximal uncoupled mitochondrial respiration (above data no shown) [135].  
Chronic exercise and hepatic HSP72 induction 
The rodents performed four weeks of voluntary wheel running (VWR), treadmill 
endurance exercise (TM-END), or treadmill interval sprint training (TM-IST). These groups were 











Figure 17. Various exercise modalities in rodents. 
Rats were split into four groups: Sedentary (SED), Voluntary Wheel Running (VWR), Treadmill 
Endurance Exercise (TM-END), and Treadmill Interval Sprint Training (TM-IST). Interventions 




We compared hepatic induction of HSP72 between these various types of chronic 
exercise (Figure 18). Following four weeks of exercise, there was no difference in HSP72 
protein induction between SED and VWR rats, however we did see a significant increase in 
HSP72 induction in the treadmill exercise groups. Four weeks of TM-IST resulted in an 8-fold 
increase in HSP72 protein expression (P < 0.001). TM-END had a robust effect on HSP72 
compared to the other groups. There was a 37-fold increase in liver HSP72 protein expression 
with four weeks of endurance training (TM-END) (P < 0.001). This was a ~350% greater 









Figure 18. Hepatic HSP72 induction with various exercise modalities. 
Effects of various exercise modalities (VWR, TM-IST, and TM-END) on HSP72 induction in the 
liver.  n=6-9 per group. Analyzed by one-way ANOVA.***P < 0.001 compared to SED animals. # 




Heat shock and autophagy protein induction with endurance chronic exercise 
Due to the drastic increase in HSP72 protein expression in the liver with chronic 
endurance exercise (Figure 19A), we also evaluated expression other two other heat shock 
proteins, HSP25 and HSP60. HSP25 was increased by 32-fold (P < 0.001, Figure 19B), and 
HSP60 increased by 27% with endurance exercise (P < 0.05, Figure 19C). Due to past work 
linking exercise and autophagy [404, 446-450] and also possibly HSPs and 
autophagy/mitophagy [317], we also evaluated autophagy protein expression with endurance 
chronic exercise. We found a 56% increase in the expression of microtubule-associated protein 
1 light chain 3 (LC3-II) with endurance exercise (P < 0.05, Figure 19D). LC3 is lipidated and 
becomes LC3-II when autophagosomes are forming [388], thus is a maker of increased 
autophagy. The protein p62 is a selective cargo adaptor that is important for sequestration of 
organelles for autophagy. This protein is degraded with increased autophagy. We observed no 









Figure 19. Endurance exercise induces the heat shock response and alters autophagy 
protein expression in the liver.  
Following four weeks of endurance exercise training A) HSP72, B) HSP25 and C) HSP60 were 
evaluated. Autophagy protein expression of D) LC3-II and E) p62. n=6-10 per group. All were 











Acute exercise increases HSP72 induction and mitophagy protein expression 
Based on the differences we observed in hepatic HSP72 induction with chronic 
endurance treadmill exercise, we were interested in the timing of HSP72 induction with treadmill 
exercise. We performed acute treadmill exercise and collected tissues 2 hours following 
exercise to identify if HSP72 was induced rapidly following an exercise bout. In addition to 
investigating acute exercise, we also added a fasted, exercised group to our study (Figure 20). 
Fasting has been shown to induce HSPs [451, 452] and also increase autophagy [453, 454]. 
We hypothesized that fasting in addition to exercise would increase HSP72 and autophagy 
protein expression more than exercise alone. Two groups of Sprague Dawley rodents were 
exercised and fed (EX-FED) or exercised and fasted (EX-FASTED). The animals performed 
acute treadmill exercise to exhaustion. We also had a third sedentary, fed group (SED) that 
were placed on a locked treadmill during the same amount of time as the exercised animals. We 
observed a 34-fold increase in HSP72 induction in the exercised, fed group (P < 0.05) and a 50-
fold increase in HSP72 induction in the exercised, fasted group (P < 0.01, Figure 21A).  There 








Figure 20. Acute exercise in rodents.  
Rats were either sedentary (SED) or performed acute treadmill exercise. The exercised animals 
were either fed (EX-FED) or fasted (EX-FASTED). Rats were fasted or fed for 12 hours and 
then underwent one bout of treadmill exercise until exhaustion. Tissues were collected post-




We were interested in the mechanism of how acute exercise was increasing HSP72 in 
the liver. We evaluated changes in protein expression of the transcription factor for HSP72, 
Heat Shock Factor-1 (HSF-1). HSF-1 has various phosphorylation sites including serine 303 
which is an inhibitory phosphorylation site on HSF-1. We observed a 68% reduction (P=0.09) in 
HSF1 phosphorylation on serine 303 in the exercise, fasted group (Figure 21B), indicating a 
reduction in inhibitory phosphorylation of HSF-1.  
Lastly, we evaluated changes in protein expression of Parkin, the E3 ubiquitin ligase 
which targets mitochondria for degradation through mitophagy. Parkin is recruited to the 
mitochondria and activated by Pink1, which phosphorylates Parkin at serine 65 (Ser 65). 
Therefore, we evaluated Parkin phosphorylation at serine 65 as a way to look at Parkin 
activation with exercise. We found a slight increase in Parkin phosphorylation (P = 0.07) in the 






      
                
 
Figure 21. Fasting combined with acute treadmill exercise increases HSP72 induction 
and phosphorylation of mitophagy-associated ubiquitin ligase, Parkin in the liver. 
In rodents that performed acute exercise (fed or fasted) we evaluated A) HSP72, B) pHSF1 Ser 
303, and C) pParkin Ser 65 protein expression. All were analyzed by one-way ANOVA. n=2-5. 











The liver is a major metabolic organ which maintains whole-body glucose homeostasis. 
This metabolic organ goes through various acute and chronic adaptations to exercise which are 
important in the prevention of metabolic disease. Currently, differences in the hepatic metabolic 
response to various exercise modalities are not well understood. Identification of the variability 
in metabolic responses to exercise, including the heat shock response, will facilitate the 
development of exercise protocols as therapy.  
In this study, we evaluated heat shock protein induction in the liver with chronic and 
acute exercise. Additionally, with acute exercise, we investigated the combination of exercise 
and fasting. With chronic exercise, rodents performed various exercise modalities to compare 
differences in heat shock protein induction. New findings from the present study indicate that the 
HSP72 protein expression is increased with acute and chronic treadmill endurance exercise. 
HSP72 was also induced to a lesser degree with chronic interval sprint training, but not 
voluntary wheel running. With acute treadmill exercise, fasting and exercise resulted in a further 
increase in HSP72 induction compared to exercise alone. Additionally, a reduction of inhibitory 
phosphorylation on HSP72’s major transcription factor, HSF1, was also observed with exercise 
and fasting combined.  
The mechanism behind HSP72 activation requires activation and translocation of the 
transcription factor, heat shock factor 1 (HSF1). When HSF1 is activated it moves to the nucleus 
and binds to heat shock elements which allows for transcription of HSP72. Elevated levels of 
both HSP90 and HSP70 act as a feedback mechanism and negatively regulate HSF1. Once 
there is a stressor such as exercise, HSPs dissociate from HSF1 which is then free to 
translocate to the nucleus and bind to HSEs which allows for increased transcription of HSP 
genes [455]. The HSP response is rapid and powerful, but also acts through feedback inhibition, 
as eventually increased HSPs re-bind to HSF1 which inhibits transcription. HSF1 is also 
regulated by multiple post translational modifications.  Constitutive phosphorylation of serines 
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303 and 307 have an important role in the negative regulation of HSF1 transcriptional activity 
[456], while phosphorylation sites serines 230 and 326 contribute to activation of HSF1 in times 
of stress [457, 458].  Once heat shock occurs, phosphorylation of HSF1 soon follows, while 
acetylation is more delayed and coincides with the feedback inhibition of HSF1. Increased 
expression and activity of SIRT1 which deacetylates HSF1 increases the binding of HSF1 to 
DNA [458]. These intricate mechanisms allow for regulation of duration and intensity of the heat 
shock response. Studies have not investigated these mechanisms in relationship to HSP72 
activation with exercise, especially in the liver. This study has identified the reduction of 
inhibitory phosphorylation at serine 303 that occurs following acute exercise, further specifying 
the mechanism of HSP72 activation in the liver.  
Multiple types of exercise can increase the heat shock response, and the majority of 
past research has focused on skeletal muscle. Heat shock protein increases can be detected 24 
hours or up to a week after an exhaustive bought of exercise in skeletal muscle, and chronic 
endurance or resistance training protocols have also been shown to increase HSP72 in skeletal 
muscle [336, 340-343, 459-463]. Many of these effects are intensity-dependent. HSP72 
induction is increased with exercise intensity with aerobic and resistance exercise [338, 340, 
342, 343]. It was also found that treadmill endurance training results in an increase in HSP72 
and HSF1 expression in the liver [429]. Additionally, acute exercise has also been shown to 
increase HSP72 in the liver, with multiple waves of HSP72 induction within 48 hours of exercise 
[366]. These studies identified the importance of heat shock proteins as a part of the complex 
molecular and metabolic adaptations following exercise. However, this is the first study to 
compare various exercise modalities along with HSP72 induction in the liver. In this study, the 
37-fold increase in HSP72 induction observed with chronic treadmill exercise and the 34-50-fold 
increase (fasted and fed) in HSP72 induction observed with acute treadmill exercise is equal to 
or much greater than induction that has been observed in skeletal muscle [429]. These results 
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suggest that robust HSP72 induction could have a major role in post-exercise hepatic 
adaptation.  
HSP72 is the highly inducible heat shock protein and has been identified to be important 
in metabolic function, however we also observed induction of other heat shock proteins (HSP25 
and HSP60) with chronic endurance exercise. HSP25 works as a molecular chaperone and 
protects against oxidative and thermal stress [464-466]. This protein also seems to be important 
for skeletal muscle to recover from exercise [333, 463, 467, 468]. Additionally, HSP60 is 
important for mitochondrial function through aiding in correct folding of proteins into the 
mitochondria [440, 469, 470]. HSP60 has also been shown to be induced by heat and exercise 
[440, 471, 472]. Future work would need to delineate the importance of these individual proteins 
in relation to HSP72 in the liver.  
In addition to studying the heat shock response following acute and chronic exercise, we 
also identified changes in autophagy and mitophagy protein expression with exercise. 
Autophagy involves a complex set of mechanisms which leads to the targeted degradation of 
organelles. Organelles are essentially tagged and marked for degradation, and are attached to 
the forming autophagosomes. LC3 lipidation which then forms LC3-II is a part of this process 
[388]. Additionally, p62, a polyubiquitin-binding protein, aids in the tethering of organelles to the 
autophagosome. Autophagosomes then fuse with the lysosomes resulting in the degradation of 
p62 and targeted organelles. Studies have shown that increased LC3-II and reduced p62 
protein expression indicate the presence of increased autophagy [53, 403]. LC3-II is also 
increased with increased mitophagy [53], the targeted degradation of mitochondria. 
In response to four weeks of chronic endurance treadmill training we observed an 
increase in LC3-II accumulation with no change in p62. This suggests a possible increase in 
autophagosome formation following four weeks of chronic treadmill exercise. Autophagy may be 
an important mechanism in the prevention of excess hepatic steatosis, as autophagy can be 
important for the degradation of lipids, called lipophagy [473].  Additionally, autophagy has been 
119 
 
demonstrated to be essential for glucose homeostasis [262]. Due to its effect on LC3-II 
accumulation, exercise may be a potential treatment modality which could treat liver steatosis. 
With acute and chronic treadmill exercise we also evaluated changes in mitophagy protein 
expression. Parkin is a major regulator of mitophagy through being an E3 ubiquitin ligase and 
marking mitochondria for degradation. Parkin is regulated by the protein Pink1 through the post-
translational modification. Pink1 finds dysfunctional mitochondria that have lost membrane 
potential and recruits and activates Parkin through phosphorylation of serine 65 [53].  With 
chronic exercise, we observed no difference in Parkin or phosphorylation of Parkin (data not 
shown). However, with acute exercise we observed an increase in phosphorylation of Parkin. 
This pattern was very similar to our observations of HSP72 with acute exercise, with a slight 
increase of each protein with the fed, exercised group and a further increase in the fasted, 
exercise group.  
This is the first study to both identify the response of HSP72 and autophagy and 
mitophagy proteins with exercise. Additionally, to our knowledge, this is the only study to identify 
these changes with exercise and the combination of fasting and exercise. This is important 
since HSP72 has been linked to autophagy and mitophagy processes in past work [269, 317]. 
Overexpression of HSP72 in skeletal muscle was shown to increase autophagy in response to 
fasting [269]. Additionally, Drew et al showed that HSP72 can bind to Parkin, aid in Pink1 
binding and increase mitochondrial degradation through mitophagy. Mice with a loss of HSP72 
have Parkin that is non-functional. This is demonstrated through increased accumulation of 
damaged mitochondria. Therefore, HSP72 activation with exercise, and possibly through a 
combination of exercise and fasting, may activate autophagy and mitophagy pathways and 
maintain a group of higher-functioning mitochondria in the liver.  
It is important to connect the results from this study to past results from Fletcher et al. 
[135]. Their group found that all types of chronic exercise (VWR, TM-END, and TM-IST) 
increased mitochondrial respiration and also individually demonstrated their own unique 
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improvements in mitochondrial function. It is interesting that in our study, we found robust 
increases in LC3-II and also HSP72 mainly in the TM-END group, and not in all exercise groups 
as they observed with mitochondrial respiration. We also observed increased HSP72 and 
phosphorylation of the mitophagy protein, Parkin, with acute treadmill endurance exercise. 
These results could be important when prescribing exercise to patients with non-alcoholic fatty 
liver disease or other metabolic conditions that already have mitochondrial damage and 
impairments [202, 205, 226, 227, 253, 254]. It may not be the best approach initially to perform 
types of exercise that increase respiration through damaged, ROS producing mitochondria. 
Initially, maybe the best treatment approach for this population would be a type of exercise that 
would activate the degradation pathways autophagy and mitophagy in order to first degrade 
unhealthy mitochondria and other organelles. This study would suggest that endurance treadmill 
exercise may be the best exercise modality to activate both HSP72 and degradation pathways 
acutely and chronically. 
There are a few limitations to this study that limit study conclusions. Future studies will 
be needed to further identify the effects of acute and chronic exercise on hepatic autophagy and 
mitophagy protein expression. Specifically, the usage of a lysosomal inhibitor such as leupeptin 
would be needed to fully identify an increase in autophagy with exercise. This compound allows 
the identification of true autophagy flux. In future studies, the use of leupeptin will be necessary 
to recognize that autophagy or mitophagy is increased with both chronic and acute exercise. 
The addition of fasting to exercise in this study is a novel approach, especially since studies 
have not identified the effect of this combination on HSP72 or autophagy protein expression. 
However, the lack of a fasting sedentary group limits the experiment’s conclusions. It is 
unknown if exercise and fasting were additive like suggested above, or if fasting alone would 
increase HSP72 expression and phosphorylation of Parkin in the liver to maximum levels. 
Future work will need the addition of a fasting, sedentary group to answer this question.   
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In addition to HSP72, past work has found a link between reduced HSF1 protein content 
to the development non-alcoholic fatty liver disease [264]. HSF1 has also been linked to 
regulation of mitochondrial biogenesis and enzyme function [324]. It would be necessary to 
identify if it is the HSP72 activity, or activity of its upstream regulator, HSF1, that has the primary 
effect on liver metabolism. The development of a liver-specific HSP72 knockout model would 
aid in answering this question. Future experiments using an HSP72 liver-specific knockout 
along with leupeptin during acute and chronic exercise would identify if this protein is essential 


























Figure 22. HSP72 induction in the liver and activation of mitophagy.  















The activation of HSPs has been proposed as a potential target in preventing and 
treating metabolic dysfunction [318]. Based on our data, exercise could be an appropriate 
approach to activate HSPs in the liver and improve hepatic metabolism through autophagy and 
mitophagy (Figure 22). Acute and chronic exercise may improve hepatic mitochondrial quality 
through inducing HSP72. This approach could be specifically effective as treatment for non-


















































Past work has solidified that HSP72 induction is essential in skeletal muscle and whole-
body metabolism. Our recent work has identified that HSP72 is also important for lipid 
metabolism in skeletal muscle and liver in two different populations with metabolic dysfunction:  
in a postmenopausal model with metabolic syndrome and also in NAFLD.  We have also 
identified that HSP72 can be induced in the liver with exercise, and may be linked to changes in 
autophagy/mitophagy. These experiments further solidify the importance of HSP72 in lipid 
metabolism and mitochondrial health in various metabolic tissues.  
 
5.1 HSPs, JNK, and Fatty Acid Oxidation 
 Metabolic disorders, including metabolic syndrome in postmenopausal women and 
NAFLD, lead to increased inflammation throughout the body which exacerbates insulin 
resistance  [163, 165, 167]. Pro-inflammatory stress kinases such as PKC, IKKβ, and JNK are 
active in insulin resistent rodents [163, 164]. This occurs in various tissues including skeletal 
muscle, adipose, and liver [165, 167, 474]. One source of JNK activation is increased lipid and 
glucose exposure that occurs with metabolic dysfunction [475, 476]. Our laboratory and others 
have demonstrated an inverse relationship between HSP72 induction through heat or 
pharmacological activation and JNK activation in the skeletal muscle and liver [267, 268, 295, 
297]. Di Naso et al. also observed an inverse relationship between HSP72 and JNK activation 
with NAFLD and NASH progression [264]. This is important since JNK can lead to dysregulation 
of lipid handling and mitochondrial function, thus inhibiting mitochondrial respiration and 
increasing ROS [163, 166, 167, 169, 170]. Prevention of JNK activation may be an approach to 
prevent metabolic disease not only through maintaining insulin signaling but also through 
increasing fatty acid utilization. This is especially important since it has been shown very 
recently in rodents that pharmacological inhibition of JNK relieved NAFLD [477]. Both JNK and 
HSPs have been shown to inhibit each other [286, 287, 298-300]. Activation of HSPs through 
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exercise, heat or pharmacological interventions may be a necessary strategy to prevent pro-
inflammatory pathway activation.  
 Past work and our current studies have shown that HSPs increase mitochondrial 
function in the skeletal muscle [269, 317] and in the liver. Specifically, in our study, we observed 
reduced fatty acid oxidation with a loss of HSP72 in primary hepatocytes. The mechanism 
through which HSP72 can protect mitochondrial function, specifically in the liver, is still not well 
understood. We propose that mitochondrial function could be partially maintained through HSP 
induction and prevention of JNK activation. We believe this mechanism occurs in the liver, 
however skeletal muscle mechanisms could be similar. 
The contribution and mechanism of FAO impairment in NAFLD development continues 
to be unclear. Past research has identified that JNK may contribute to reduced fatty acid 
oxidation in liver and skeletal muscle. Specifically, knockdown of JNK in hepatocyte culture and 
in vivo was shown to reduce lipid synthesis, increase fatty acid oxidation, and improve insulin 
sensitivity [478, 479]. This mechanism seems to be present in skeletal muscle as well, since 
inhibition of JNK activation increases fatty acid oxidation in muscle [480].  
A more recent study by Vernia et al. demonstrated that JNK regulates fatty acid 
oxidation through PPARα [289]. PPARα is a transcription factor that is highly expressed in 
metabolic tissues including the liver and regulates many aspects of fatty acid metabolism, 
ketogenesis, as well as fibroblast growth factor 21 (FGF21) gene expression [481-487]. FGF21 
is a hepatokine and myokine which improves systemic metabolic function through many 
peripheral tissues. Importantly, it regulates fatty acid oxidation and ketogenesis gene expression 
in hepatocytes [484]. Whole-body as well as liver-specific deletion of PPARα in mice results in 
increased steatosis, impaired fatty acid metabolism and ketogenesis, as well as a reduction in 
expression of FGF21 in the liver [488-493]. Increased lipid storage, oxidative stress and lipid 
peroxidation that occur with hepatic steatohepatitis can be avoided through PPARα activation 
[490, 494]. PPARα activity allows the liver to adjust to increased influx of lipids in response to 
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high lipid exposure, and is a possible pharmacological target to treat liver disease. Therefore, 
PPARα-mediated activation of FGF21 may be essential in hepatic lipid handling and prevention 
of steatosis [484].  
PPARα is regulated by many signaling pathways, including pro-inflammatory molecules. 
Vernia et al showed that JNK inhibits hepatic fatty acid oxidation through the PPARα and 
FGF21 pathway [289]. They found that JNK activity is necessary to maintain expression of the 
PPARα transcriptional corepressors NCOR1 and NRIP1. These corepressors act by binding to 
PPARα and reducing transcription, thus reducing expression of FGF21, fatty acid oxidation and 
ketogenesis genes [289]. This group also demonstrated that JNK deficiency in the liver of HFD-
fed mice results in increased FGF21 expression and improved whole-body metabolism [289]. 
These improved metabolic outcomes were dependent on FGF21 expression. This pathway may 
be important in other tissues besides the liver, since FGF21 has also been shown to be a 
powerful myokine affecting whole body metabolism [495, 496], and JNK is also increased in the 
muscle with metabolic syndrome and diabetes [282]. Inhibition of PPARα -related pathways by 
JNK could contribute to a reduction of fatty acid oxidation during the progression of liver disease 
and skeletal muscle metabolic dysfunction.  
A close co-regulatory relationship between HSPs and JNK has been established in 
skeletal muscle, [165, 167, 267, 268, 286, 287, 295, 297-300] and studies are beginning to 
corroborate this relationship in the liver [264, 295]. In future studies, it will be necessary to 
recognize 1) is JNK activation a major contributor to increased steatosis in NAFLD through 
inhibition of the PPARα/FGF21 pathway, and 2) can HSP induction prevent JNK-mediated 
inhibition of fatty acid oxidation and protect from the development of steatosis. Our findings 
demonstrate in primary hepatocytes that following the loss of HSP72, there is a reduction in 
fatty acid oxidation and increased lipid accumulation. It is possible that with a loss of HSP72, 
JNK activation increases and inhibits PPARα/FGF21 pathway, reduces fatty acid oxidation and 
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increases lipid storage. Further research is needed to determine these HSP72-mediated 
mechanisms are present in hepatocytes and can protect against the development of NAFLD.  
 
5.2 Autophagy and HSP72 
Autophagy is an important cellular degradation process which degrades organelles and 
maintains cellular function. Defects in autophagy have been implicated in the development of 
metabolic syndrome and glucose insensitivity in skeletal muscle [52, 262]. Additionally, 
autophagy degradation of lipids (lipophagy) has also been shown to be important for liver 
homeostasis [259]. Autophagy is also impaired in livers of obese rodents which leads to ER 
stress and insulin resistance [260]. However, another study found that autophagy deficiency in 
skeletal muscle can lead to FGF21 induction and overall protection from insulin resistance [495]. 
Therefore, the role of autophagy is unclear, and the mechanisms that lead to autophagy 
dysfunction in metabolic disease are unknown.  
In our studies, we found changes in autophagy gene expression in skeletal muscle and 
liver in two different models.  We found that ERα-/- rats develop insulin resistance and skeletal 
muscle metabolic dysfunction, similar to what is observed in postmenopausal women. We also 
observed a reduction LC3-II protein content in skeletal muscle, which suggests a reduction in 
autophagosome accumulation in the insulin-resistant muscle. This reduction in autophagy may 
contribute to cellular organelle dysfunction and skeletal muscle insulin resistance. Additionally, 
in a separate study, we investigated expression of autophagy proteins in the liver following 
chronic exercise. Four weeks of chronic endurance treadmill exercise increased LC3-II protein 
content in the liver and suggests that chronic exercise increased autophagosome accumulation. 
This is in agreement with other studies in skeletal muscle which have shown that exercise 
increases autophagy [497]. 
In both studies, when we saw changes in autophagy protein content, we also observed a 
similar pattern of change in HSP72 content. It is logical that heat shock proteins and autophagy 
129 
 
would work together to maintain proteostasis and cellular health. In order to reach proteostasis 
there has to be a balance of protein folding and protein degradation [498]. Heat shock proteins 
are important in maintaining protein function through correct protein folding, while autophagy 
degrades dysfunctional proteins. It is possible that HSP72 could play a role in autophagic 
regulation in both skeletal muscle and liver. 
Heat stress induces heat shock proteins, and an early study showed that heat exposure 
in primary hepatocytes induced heat shock proteins, but reduced autophagy protein levels [499]. 
However, a separate study showed that heat exposure actually increases autophagy in various 
cell types including hepatocytes [500-503]. Recent studies have demonstrated an inverse 
relationship between HSF1 levels (the primary transcription factor for HSP72) and LC3-II levels 
[500, 502]. However, HSP72 overexpression in skeletal muscle increases LC3-II during fasting 
compared to fasted control animals [269]. Additional research is needed to clarify the 
relationship between HSPs and autophagy. 
It is well known that exercise increases heat shock proteins. The research area of 
exercise and autophagy activation has recently had renewed interest. Exercise has been 
demonstrated to increase autophagy in skeletal muscle [446, 504, 505]. Following exercise, 
many pathways of degradation and repair are activated, and both autophagy and heat shock 
protein regulation may be important in order to adapt to exercise [498]. Dokladny et al. proposed 
that autophagy is likely important in the initial degradation response following exercise, while the 
heat shock response is important for cellular building and protein synthesis that occurs in the 
days following exercise [498]. The coordination of these two systems likely allow for optimal 
adaptation and improvements of cellular physiology following exercise. Our studies showed that 
autophagy and heat shock proteins likely interact, especially during exercise, but more research 




In preliminary experiments, we studied the effect of HSP72 overexpression on 
autophagy flux in primary hepatocytes. First, we overexpressed HSP72 (adenoviral transfection) 
for 24 hours in growth media, and then with chloroquine (10 µM) in low serum media (0.5% 
FBS) for an additional 24 hours. Chloroquine treatment allows for assessment of autophagy flux 
by inhibiting lysosomal acidification and subsequent quantification of the upstream autophagy 
proteins that accumulate. We evaluated LC3-I which during increased autophagy flux is 
lipidated and becomes LC3-II [388]. The protein p62 is a selective cargo adaptor that is 
important for sequestration of organelles for autophagy. This protein is degraded with increased 
autophagy. As expected, chloroquine treatment increased LC3-I, LC3-II, and p62 (Figure 23A, 
B, and C). Additionally, following HSP72 overexpression, we saw a reduction in LC3-I and p62 
protein content with chloroquine treatment compared to control (Figure 23B, P < 0.001, and 
Figure 23C, P < 0.01). We did not see any change in LC3-II accumulation, a classical marker 
for autophagosome accumulation (Figure 23A).  In summary, HSP72 may regulate expression 





























Figure 23. HSP72 overexpression reduces autophagy protein expression.   
Primary hepatocytes were treated with an HSP72 overexpressing adenovirus for 24 hours in 
Williams E growth media, and then with chloroquine (10 µM) in Williams E media (0.5% FBS) for 
24 hours A) LC3-II, B) LC3-I and C) p62 were compared between groups. D) Representative 
blot of HSP72 overexpression.  n=3 wells per group from one animal. Analyzed by one-way 
ANOVA. *P < 0.05 between control and HSP72 adenovirus groups, and † P < 0.05 between 







Although impairments in autophagy occur with metabolic disease, the mechanism of 
how this develops is largely unknown. Increased cellular lipid exposure has been proposed as a 
possible cause for reduced autophagy with obesity and metabolic diseases [506]. Saturated 
fatty acids are abundant in the Western diet. They may contribute to lipotoxicity and 
development of NAFLD through activation of JNK, ER stress, oxidative stress, and 
mitochondrial dysfunction [507]. However, findings from studies investigating the effect of a lipid 
challenge on autophagy are inconsistent. Koga et al. found chronic exposure to a lipid challenge 
through a 16-wk HFD in rodents resulted in a reduction in autophagy rate in the liver [506]. 
However, Mei et al. found that acute exposure of palmitic acid, a saturated fatty acid, had no 
effect on autophagy or slightly suppressed autophagy, while the unsaturated fatty acid oleic acid 
induced autophagy [508]. More research is needed to fully understand lipid regulation of 
autophagy.  
In preliminary experiments, we aimed to identify the effect of acute palmitate exposure 
and HSP72 loss on autophagy flux in primary hepatocytes. Hepatocytes were treated with 
siHSP72 for 48 hours to suppress HSP72 levels. All cells were subsequently treated with 
chloroquine for 30 min before treatment with palmitate plus chloroquine for an additional 24 
hours in order to assess autophagy flux.  We evaluated LC3-II, LC3-I and p62 protein 
expression following a loss of HSP72. Similar to the findings of Wei et al., we observed no 
significant difference in autophagy protein expression following palmitate exposure (Figure 24A, 
B and C) [508]. Additionally, we did not observe differences in protein expression between 
control siRNA and siHSP72 treated hepatocytes. Combined treatment with palmitate and 
siHSP72 treatment had no effect on LC3-II and LC3-I (Figure 24A, and B), but significantly 
increased p62 protein content (P < 0.05, Figure 24C). We observed variability between groups, 
and the presence of outliers which may have affected our results and should be addressed in 










Figure 24. A loss of HSP72 and palmitate treatment increases autophagy protein 
expression.   
Primary hepatocytes were treated with siHSP72 for 48 hours (15 nM) and then palmitate for 24 
hours (250 µM). All hepatocytes were treated with chloroquine (10 µM) for 30 min before 
treatment of palmitate plus chloroquine for 24 hours. A) LC3-II, B) LC3-I and C) p62 were 
compared between groups D) Representative blot of HSP72 knockdown of ~60%. n=3-6 wells 
per group from one animal. Analyzed by one-way ANOVA. *P < 0.05 between control and 







Expression of proteins involved in autophagy may increase in primary hepatocytes 
following a combination of siHSP72 and palmitate exposure in order to manage organelle 
damage that both stressors put on the cellular components. It is likely that following a loss of the 
chaperone HSP72 hepatocytes become more vulnerable to cellular stressors associated with 
metabolic disease. An increase in JNK may also contribute to altered autophagy that occurs 
during metabolic disease progression. Inhibition of JNK in rodents has been shown to relieve 
NAFLD, and also suppress autophagy [477]. Yan et al. suggested that inhibition of JNK and 
suppression of autophagy in the liver contributed to improved insulin sensitivity [477]. A loss of 
HSP72 could be a key step towards further disease progression due to the inability to induce 
the heat stress response associated with increased cellular stress and inflammation.  
 
5.3 Liver-Specific HSP72 Knockout Model 
To date, no studies have examined direct effects of HSP72 on hepatic lipid metabolism. 
The use of a novel liver-specific HSP72 knockout animal in our laboratory will be key in 
identifying the importance of HSP72 in hepatic lipid metabolism. We believe that a loss of 
HSP72 will lead to steatosis and impaired whole-body glucose homeostasis. We also expect 
that a loss of HSP72 will lead to mitochondrial dysfunction and inflammation, which will be 
further exacerbated with a HFD. Additionally, we expect that a loss of HSP72 will impact 
autophagy and mitophagy pathways. Re-introduction of HSP72 through overexpression in this 
model should rescue steatosis and inflammation that occurs with a HFD. Using this model, we 
will be able to identify the importance of both HSP72 and its transcription factor, HSF1, to liver 
metabolism. Past research has demonstrated that HSF1 and PGC-1α can work together to 
regulate mitochondrial biogenesis and whole-body metabolism [324, 325]. In the liver-specific 
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5.4 HSP72 Regulation of the Unfolded Protein Response and Proteostasis. 
Cellular stress causes unfolded proteins to accumulate in the endoplasmic reticulum 
(ER), which activates the unfolded protein response (UPR) [509-511]. This response is 
important for cellular adaptation to ER stress and prevention of ER-stress induced apoptosis 
[512, 513]. ER stress and chronic activation of the UPR causes inflammation and contributes to 
the development of insulin resistance [514-523].  
Although other HSP family proteins have been shown to be a part of the UPR [455, 524, 
525] new evidence has also identified cytoplasmic HSP72 as part of the UPR. Specifically, 
HSP72 interacts with and upregulates inositol requiring enzyme 1 α (IRE1α) signalling to the 
ER. Activation of IRE1α by HSP72 enhances cell survival through prevention of ER-stress 
induced apoptosis [526]. This mechanism may be important in HSP72- mediated metabolic 
improvements, since activation of IRE1α also has been shown to suppress lipogenesis [527]. 
 HSP72 is known to regulate mitochondrial function, but it’s possible it regulates both the 
ER and the mitochondria. Additionally, ER and mitochondria can be tightly linked through 
interactions at mitochondria-associated membranes [528]. At these interactions, the organelles 
exchange lipids and calcium which is important for regulation of cellular homeostasis and 
adaption to metabolic stressors. Future work is needed to identify the role of HSP72 at the ER 
and between the ER and mitochondria.  
HSP72 also likely impacts metabolic health through the protein’s additional 
responsibilities as a cellular chaperone. During stress, HSP72 is essential to refold misfolded 
proteins and to maintain proteostasis. One way that HSP72 may maintain proteostasis is by 
regulating proteosomal degradation and autophagy [529, 530]. Degradation pathways via 
136 
 
proteasomes and autophagy are well established, but it was recently demonstrated that 
mitochondria also function as sites for protein degradation [531]. Specifically, the chaperone 
HSP104 detangles protein aggregates allowing mitochondrial transporters to import proteins 
into the outer and inner mitochondrial membrane. Proteases in the mitochondrial matrix are then 
able to degrade the newly imported unfolded proteins. Importantly, defects in HSP70 activity 
result in increased transport of misfolded proteins into the mitochondria, causing increased 
mitochondrial damage and ROS production. This phenomenon has been confirmed in both 
yeast and human retinal pigment epithelium cells [531]. It is tempting to speculate that defects in 
HSP72 activity could contribute to mitochondrial dysfunction by trigging this alternative 
mitochondrial-dependent degradation pathway. This alternative pathway may contribute to the 
swollen, rounded appearance of the mitochondria during metabolic disease, as well as 
decreased mitochondrial function as a respiratory organelle. Additional investigation of this 
mechanism in metabolic organs should be the focus of future research.   
 
5.5 HSP72 as a Biomarker of Metabolic Health 
Researchers have shown that HSPs can be released extracellularly (eHSP), specifically 
during exercise [338, 361-364]. HSP release could allow for organ crosstalk and the spread of 
HSPs to various tissues. eHSP72 function in general is associated with activation of the immune 
system [434], and in contrast to the anti-inflammatory actions of intracellular/cytosolic HSP72 
(iHSP72), can induce activation of proinflammatory pathways. Based on this antagonistic action 
of HSP72 on the inflammatory response, the Chaperone Balance Hypothesis contends that the 
balance between eHSP72 and iHSP72 (eHSP72/iHSP72) could determine the extent of tissue 
inflammation, and thereby influence the pathogenesis of insulin resistance and type 2 diabetes 
[532]. According to this hypothesis, an intervention which lowers the eHSP72/iHSP72 ratio 
could in effect improve insulin sensitivity. Long term exercise training results in decreased 
eHSP72 and increased iHSP72 expression (as in skeletal muscle, and as we have observed in 
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the liver), supporting this hypothesis. In addition to the research supporting the many metabolic 
benefits of exercise in post-menopausal women [80-83] and also in patients with NAFLD [137-
139], the effect of exercise on the eHSP72/iHSP72 ratio could be key in preventing metabolic 
dysfunction.  
Importantly, the eHSP72/iHSP72 ratio could be a valuable biomarker for assessment of 
the inflammatory response in metabolic disease. In women, these ratios could be assessed pre- 
and post-menopause in order to identify the development of metabolic syndrome. It equally 




 These current studies have identified the importance of HSPs in various tissues and 
metabolic diseases. In this work, we identified the importance of HSPs in exercise capacity of a 
postmenopausal model and possible mechanisms of HSP and estrogen receptor interaction in 
skeletal muscle. We also investigated HSPs in an understudied organ, the liver. We identified 
the importance of HSP72 in prevention of steatosis, and the ability of acute and chronic exercise 
to induce HSPs in the liver. Intracellular and extracellular HSP levels could be a valuable marker 
of overall and tissue-specific metabolic health. Clinicians should consider safe and effective 
treatments that induce the heat shock response (e.g. heat and exercise) as viable treatments for 
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